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ABSTRACT 
An arteriovenous fistula is an abnormal direct passage between an artery and a vein. The 
existence of an arteriovenous fistula generates a high output low total peripheral 
resistance state that resembles the hyper-haemodynamic condition of several diseases 
such as vascular injury, congenital malformation, chronic severe anemia, severe hepatic 
or renal disorders, and septic shock. In the present study, we investigated the 
haemodynamic changes in rats with chronic arteriovenous fistulae and the haemodynamic 
effects of noradrenaline, arginine vasopressin, and sodium nitroprusside in this model. 
Creation of a chronic fistula between abdominal aorta and inferior vena cava increased 
cardiac output compared to sham-operated rats. The haemodynamic factors when 
compared to respective values in sham-operated rats changed in the following ways: 1) 
total peripheral resistance and resistance to venous return decreased; 2) heart rate and 
cardiac contractility based on dP/dt values recorded remained stable at the baseline level; 
and 3) blood volume and mean circulatory filling pressure increased. The augmentation 
of total blood volume, mean circulatory filling pressure and reduction in vascular 
resistance together contributed to the increase in cardiac output. 
Noradrenaline infusion did not change the cardiac index in rats with chronic 
arteriovenous fistulae. Administration of noradrenaline 1) increased total peripheral 
resistance and resistance to venous return; 2) increased heart rate and cardiac contractility 
based on dP/dt values recorded; and 3) did not change total blood volume but increased 
mean circulatory filling pressure. The positive effects of noradrenaline on heart rate, 
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cardiac contractility, and total body venous tone tended to increase cardiac index. 
However, the increase of cardiac index was prevented due to the increase in total 
peripheral resistance and resistance to venous return. 
Administration of arginine vasopressin did not change the cardiac index in rats with 
chronic arteriovenous fistulae. Upon arginine vasopressin infusion, 1) total peripheral 
resistance and resistance to venous return increased; 2) heart rate did not change while 
cardiac contractility increased based on dP/dt value recorded; and 3) total blood volume 
and mean circulatory filling pressure increased. Unlike its actions in the intact animal, 
administration of arginine vasopressin ·in rats with chronic arteriovenous fistulae reversed 
the preload-afterload mismatch by increasing mean circulatory filling pressure and total 
blood volume with little effect on resistance to venous return. Therefore, cardiac index 
did not fall despite of elevation of the afterload. 
Administration of sodium nitroprusside had limited effects on cardiac index in rats with 
chronic arteriovenous fistula. The circulatory parameters altered in the following manner: 
1) total peripheral resistance and resistance to venous return remained at the baseline 
level; 2) heart rate did not change while cardiac contractility decreased at the highest dose 
based on dP/dt value recorded; and 3) total blood volume and mean circulatory filling 
pressure was kept unchanged. Due to the special condition in our experimental model 
such as low vascular resistance and maximal vasodilation, administration of sodium 
nitroprusside had limited haemodynamic effects. 
iv 
In conclusion, in rats with well compensated chronic arteriovenous fistulae vasoactive 
agents have little effects on cardiac output. Therefore, in diseases resembling the 
pathophysiology of a chronic arteriovenous fistula such as septic shock administration of · 
these drugs may have limited effect and little benefit. 
v 
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1. Introduction 
1.1. Regulation ofCardiac Output 
Cardiac output is the quantity of blood pumped into the aortic arch each minute by the 
heart (Guyton & Hall, 2000a). This also is the amount of blood that flows through the 
whole circulation (Guyton & Hall, 2000a). The stream of the blood flow transports 
nutrients, wastes and hormones from one part of the body to another therefore 
maintaining a constant internal environment (Guyton et a/., 1973a). A substantial 
decrease in cardiac output can lead to detrimental effects on cellular functions because of 
failure to deliver adequate nutrients or timely remove wastes (Guyton et a/., 1973a). 
Due to its important role, cardiac output is delicately regulated to provide enough blood 
to individual tissues to maintain their functions (Guyton, 1981 ). According to Guyton 
(1981 ), cardiac output is regulated by four basic circulatory factors: total peripheral 
resistance (TPR), heart pumping capacity (heart rate and cardiac contractility), blood 
volume and vascular compliance. 
Venous return is the quantity of blood flowing from the veins into the right atrium each 
minute (Guyton & Hall, 2000a). It should equal cardiac output in the steady state with 
exceptions when blood is temporarily being stored in or removed from the heart and 
lungs during a few heart beats (Guyton & Hall, 2000a). Venous return is determined by 
the balance between the pressure gradient that drives the venous return and the resistance 
2 
to venous return. 
1.1.1 Resistance 
Resistance is the impediment to blood flow in a vessel (Guyton & Hall, 2000b). It can 
not be measured by direct means but calculated from the equation below (Guyton & Hall, 
2000b): 
Resistance = Pressure gradient + Blood flow 
The resistance of the entire systemic circulation is called total peripheral resistance (TPR) 
(Guyton & Hall, 2000b). Similarly, resistance in arteries and veins is called arterial 
resistance and venous resistance, respectively. Moreover, resistance to venous return is 
the combined resistance of all the vessels up to the right atrium from venous locations 
where the intravascular pressure is equal to the pressure when circulation is stopped and 
equilibrated (Bower & Law, 1993). It has been suggested that resistance to venous 
return accounts for approximately 5% ofthe TPR (Bower & Law, 1993). 
At each level of atrial pressure, the ventricular output is nearly reciprocally related to the 
square root of the resistive load (Guyton et al., 1973b). It was postulated that resistance 
may alter cardiac output either by changing the load on the ventricle or the ease with 
which blood flows through the vessels back to the heart (Guyton et al., 1973b). To 
support their suggestion, Guyton et al. (1959) conducted a series of experiments in which 
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the total vascular resistance was increased by elevating arterial resistance and venous 
resistance. Comparatively, a substantial increase in the TPR caused by arterial 
embolization resulted· in only a moderate reduction in cardiac output (i.e. a 400% 
increase in TPR only decreased cardiac output by 30%) (Guyton et al., 1959). In 
contrast, an increase of TPR by 25% above the control level by the inflation of a cuff on 
vena cava reduced cardiac output by approximately 30% (Guyton et al., 1959). Based 
on these observations, it is evident that an increase in resistance in veins has a much 
greater impact on the cardiac output. This is because in spite of elevation of the 
impediment to blood flow, the pressure gradient for venous return (PGVR) was 
decreased simultaneously in the presence of venous resistance augmentation (Guyton et 
al., 1959). 
In contrast, when TPR is decreased greatly by opening a large arteriovenous fistula 
(AVF), the cardiac output immediately increases and remains at this higher level as long 
as the fistula is maintained (Guyton & Sagawa, 1961; Huang et al., 1992). The reduced 
TPR decreases the impedance to the blood flowing back .to the heart. In combination 
with volume expansion, more blood is able to flow back into the heart. In tum, the 
heart responds by pumping out extra blood in accordance with Frank-Starling's law 
(Guyton & Sagawa, 1961; Huang et al., 1992). 
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1.1.2. H~art pumping capacity 
Cardiac output is also finely regulated by the sympathetic and parasympathetic nervous 
system which innervates the heart at different levels (Guyton & Hall, 2000c) .. The 
neurotransmitters released by nerves that innervate the heart alter the pumping 
effectiveness. This is chiefly achieved in two ways: 1) changing the heart rate and/or 2) 
changing the strength of the contractile force of the myocardium (Guyton & Hall, 
2000c). 
There is substantial evidence to suggest that an increase in heart rate has a biphasic 
impact on the cardiac output. In experimental situation in dogs, simple elevation of 
heart rate from 55 to 108 beats/min only results in 7.7% increase in cardiac output in 
experimental dogs (Nakano, 1964; Cowley & Guyton, 1971). Cardiac output then is 
maintained at the highest level when heart rate is between I 08 and 148 before it declines 
(Nakano, 1964; Cowley & Guyton, 1971). Therefore, the shape of the 
heart-rate-cardiac-output curve resembles a "bell". The 7.7% increase of cardiac output 
(the left side of the "bell" curve) is brought about by an elevation of the heart rate 
without substantial reduction in stroke volume. The highest cardiac output achieved 
during the optimal range for heart rate (the plateau of the "bell" curve) is the 
consequence of simultaneous reduction in stroke volume and elevation of heart rate 
(Cowley & Guyton, 1971). The decrease of cardiac output when the heart rate increases 
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beyond a critical value (the right side of the "bell" curve) is caused, at least, partially by 
shortened diastolic filling period of ventricles as well as incomplete ventricular 
relaxation (Nakano, 1964; Sugimoto et al., 1966; Cowley & Guyton, 1971). 
There is evidence to support the view that cardiac contractility is positively correlated to 
cardiac output if other circulatory factors remain constant. In an isolated canine heart 
which was paced at a constant rate (211 beats/min), fed with fixed venous reservoir and 
connected to unchanged peripheral resistance (controlled by the valve in the artificial 
circuit), reduction of the contractility due to efferent vagal stimulation consistently 
diminished stroke volume resulting in a reduction in the ventricular output (Degeest et al., 
1965). In a similar preparation of isolated, perfused, working guinea-pig heart, when 
preload and afterload were kept constant, 2 x 10-7 M of digoxin (a positive inotropic 
agent) increased cardiac output without altering heart rate (Zannad et a/., 1982). The 
enhanced performance of the heart was suggested to be the result of increased 
contractility induced by digoxin (Zannad et al., 1982). The basis for the relationship 
between contractility and cardiac output is that decreased strength of heart beat limits the 
amount of the blood volume being expelled from the heart to the systemic circulation 
thus leading to decreased cardiac output (Guyton et al., 1973c). On the other hand, 
enhanced heart beat displaces extra quantity of blood from the heart to the remainder of 
the circulation, which is then responsible for the increase in cardiac output (Guyton et al., 
6 
1973c). 
It has been suggested that the effect of heart rate on the cardiac output is dependent on 
the level of venous return. The heart was reported to pump more quickly and deliver 
more blood at the higher venous return level which can be caused by opening a large AVF, 
noradrenaline infusion, or sympathetic stimulation (Sugimoto et al., 1966; Cowley & 
Guyton, 1971 ). In the latter condition, the left side of the "bell" curve will be moved 
further upward and rightward (Cowley & Guyton, 1971). Meanwhile, the effect ofthe 
heart rate on the cardiac output is more obvious when venous return is increased 
(Sugimoto et al., 1966). 
Similarly, in one investigation in which Guyton et al. (1957) replaced the right ventricle 
with a mechanical pump, the effect of unlimited increase in both heart rate and cardiac 
contractility was examined. In the latter experiments, as heart pumping capacity 
increased, venous return curve reached the maximum value and remained at a plateau 
level when the right atrium pressures were more negative than -2 to -4 mmHg (Guyton· et 
al., 1957). This implies that no matter how hard the heart pumps the cardiac output 
would not exceed the plateau level of the venous return curve at the steady state. The 
simple explanation is that the amount of blood the heart pump is much more than the 
venous system can feed the heart. 
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The rate of change of the ventricular pressure with respect to time (i.e. dP/dt) can be an 
indicator of the level of contractility (Guyton & Hall, 2000c). In experimental studies, 
the peak dP/dt represents the maximal rate of rise in ventricular pressure and is often 
used for comparing the contractility of hearts in different functional states (Mason, 1969; 
Guyton & Hall, 2000c). However, the dP/dt value can be affected by factors other than 
the strength of the heart beat such as the loading conditions of the heart (Mason, 1969; 
Guyton & Hall, 2000c ). It has been shown that a substantial increase in ventricular 
preload or a huge rise in ventricular afterload is capable of increasing dP/dt without a real 
elevation of cardiac contractility (Mason, 1969). The increment of preload can be 
reflected by a climb of the ventricular end-diastolic pressure or an increase in blood 
volume whereas the augmentation of the afterload can be manifested as an increment of 
the arterial diastolic pressure (Mason, 1969). Therefore, dP/dt may not increase upon 
the elevation of the cardiac contractility if the afterload falls extensively (Mason, 1969). 
On the other hand, dP/dt can increase while cardiac contractility is decreasing (Mason, 
1969). This might happen when there is a large increase in preload (Mason, 1969). 
Furthermore, a direct linear correlation has been shown between peak dP/dt and heart 
nite in an areflexic canine preparation (Mason, 1969). Therefore, caution must be 
exercised when evaluating changes in cardiac contractility using dP/dt as the parameter 
In VIVO. 
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1.1.3. Blood Volume 
' 
Acute volume expansion can immediately increase cardiac output as well as the mean 
arterial pressure (Prather et al., 1969; Cevese & Guyton, 1976). . The hyperdynamic 
effect is more significant in headless dogs than in anaesthetized ones (Prather et a!., 1969; 
Cevese & Guyton, 1976). The acute volume expansion first increases the filling of the 
systemic circulation. Subsequently, the elevation of the fullness of systemic circulation 
increases the preload of the heart. This consequently increases the cardiac output due to 
Frank-Starling's law (Guyton et al., 1973d). However, it has also been established that 
after 90-120 minutes, cardiac output is able to fall back to the control level despite the 
persistent elevation of blood volume (Prather et al., 1969; Cevese & Guyton, 1976). 
Nervous and/or stress relaxation of the capacitance blood vessels and trans-capillary fluid 
exchange are thought to contribute to the reduction of cardiac output after a prolonged 
period of volume expansion (Prather et a!., 1969; Guyton et a!., 1973d). It is also 
recognized that if the pumping capacity remains normal, acute hemorrhage decreases 
cardiac output while quick transfusion reverses the deficiency in cardiac output (Guyton 
eta!., 1958). 
1.1.4. Vascular compliance 
Vascular compliance is the total quantity of blood that can be stored in a given portion of 
the circulation for each millimeter of mercury rise in pressure (Guyton & Hall, 2000d). 
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However, it is difficult to quantify vascular compliance in vivo. According to Tabrizchi 
and Pang (1992), Grodins formulated four equations to quantify the vascular factors 
influencing the systemic circulation: 
Q = (Pa- Pv)IR 
Pa = BVa!Ca 
Pv = BVviCv 
BV=BVa+BVv 
(1) 
(2) 
(3) 
(4) 
Where Q is cardiac output during the steady state; R is systemic resistance; Pa and Pv are 
arterial and venous pressures; Ca and Cv are· art~rial and venous compliances; BV a and 
BV v are arterial and venous blood volumes, respectively. By rearranging the four 
equations (1-4), equation (5) and (6) are obtained (Tabrizchi & Pang, 1992): 
Pa = BV/(Ca + Cv) + CvRQ/(Ca +Cv) 
Pv = BV/(Ca + Cv)- CaRQ/(Ca +Cv) 
When Q = 0, the corollary is that (Tabrizchi & Pang, 1992): 
Pa = Pv = BV/(Ca + Cv) 
(5) 
(6) 
(7) 
This equilibrium of the pressure after blood flow cessation is synonymous with Guyton's 
term "mean circulatory filling pressure" (Pmcr) (Guyton eta/., 1954). It is apparent from 
equation (7) that the Pmcf is directly proportional to the total blood volume and inversely 
proportional to the overall vascular compliance. Since venous compliance is many 
times greater than arterial compliance, Pmcf is mainly a reflection of the body's total 
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venous t~ne provided blood volume remains unchanged (Tabrizchi & Pang, 1992). 
Mathematically, Pmcf reflects the ratio of the total blood volume to the ability of the 
circulatory system to hold the volume (Prather et al., 1969). Total spinal anaesthesia 
lowers Pmcf while increasing vasomotor tone or acute volume expansion increases Pmcf 
(Guyton et a/., 1954). Experimental evidence seems to suggest that the relationship 
between blood volume and Pmcf is almost linear (Holman, 1940; Guyton et al., 1954; 
Guyton et al., 1973e ). Furthermore, without reflexes, only slight alterations of the 
blood volume can markedly affect the Pmcf (Holman, 1940). It has been shown that 
venous return increases approximately in proportion to the pressure difference between 
Pmcf and right atrial pressure if resistance to venous return remains constant (Guyton et 
a/., 1955). The pressure gradient is called PGVR. Therefore, in the latter condition, 
cardiac output will be also increased by the increment of PGVR at a steady state. This 
is so because Pmcf increment increases cardiac output by intensifying the force that 
pushes the blood to the right atrium. In addition, a rise in P mcf will distend the veins 
leading to the right atrium. The venodilation consequently decreases the impedance to 
venous return which also contribute to the elevation of cardiac output (Guyton et al., 
1955). 
In summary, I) a rise in vascular resistance tends to decrease cardiac output and a fall in 
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vascular resistance tends to increase cardiac output; 2) heart rate has a biphasic impact on 
cardiac output in a way that the heart-rate-cardiac-output curve resembles a "bell"; 3) 
cardiac contractility is positively related to cardiac output when preload, afterload, and 
heart rate are kept constant; 4) acute change of blood volume alters cardiac output in the 
same direction; 5) Pmcris an indicator of total body venous tone provided blood volume is 
unchanged; 6) an increase in Pmcr is a contributory factor to increase cardiac output. 
1. 2. Haemodynamic effects of noradrenaline 
Noradrenaline (norepinephrine, levarterenol) is a major chemical transmitter liberated by 
mammalian postganglionic sympathetic nerves (Von Euler, 1952; Von Euler, 1955; 
Westfall & Westfall, 2006). Noradrenaline elicits vasoconstriction and raises the blood 
pressure by stimulating a-adrenergic receptor (Bellomo & Giantomasso, 2001) and 
increases coronary blood flow possibly through direct P2-adrenaceptor activation 
(Westfall & Westfall, 2006). As a pressor hormone and physiological vasoconstrictor, 
noradrenaline plays an important role in blood pressure homeostasis (Von Euler, 1952; 
Von Euler, 1955). Also, it is the standard therapy in the situation when there is a need 
to increase blood pressure or stimulate the heart (Von Euler, 1952; Von Euler, 1955; 
Westfall & Westfall, 2006). As well, in clinical situations in which the endogenous 
noradrenaline is depleted supplemental noradrenaline is recommended (Von Euler, 1952; 
Von Euler, 1955). However since excessive amounts of noradrenaline can cause severe 
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hypertension, careful blood pressure monitoring is generally recommended during 
systemic administration of this agent (Westfall & Westfall, 2006). Reduction of blood 
flow to organs such as kidney and intestines is another potential disadvantage of 
noradrenaline administration (Bellomo & Giantomasso, 2001; Westfall & Westfall, 2006). 
Noradrenaline seems to have dose dependent biphasic action on cardiac output (Takacs, 
1965; Tabrizchi, 2001 ). Reportedly, cardiac output is not changed significantly during 
intravenous infusion of noradrenaline at moderate doses (0.3, 0.4, and 1.0 J..Lg/kg/min or 
intraperitoneally 20 and 1 00 11g/kg) (Takacs, 1965; Tabrizchi, 2001 ). However, cardiac 
output was markedly increased when noradrenaline was infused intraperitoneally at a 
dose of 500 J..Lg/kg (Takacs, 1965). Similarly, Imms eta/. (1974) reported a significant 
increase in cardiac index (CI), which is cardiac output divided by body weight, at the 
infusion rate of 1. 7 11g/min. Moreover, noradrenaline has been shown to increase 
ventricular output in the isolated perfused rat heart with constant preload and afterload by 
enhancing stroke volume and heart rate (Geier et al., 2002). Noradrenaline infusion 
(0.4-3.0 11g/kg/min) also results in a significant increase in cardiac output in cats with 
suppressed autonomic reflexes and respiratory movements (Bower & Law, 1993). 
Noradrenaline dose dependently increases the mean arterial pressure, systolic pressure, 
diastolic pressure and pulse pressure (Takacs, 1965; Young et al., 1992; Bower & Law, 
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1993; Westfall & Westfall, 2006). Arterial resistance and resistance to venous return 
were shown to increase significantly at doses of 0.3 and 1.0 l!glkg/min (lmms et al., 1974; 
Pang & Tabrizchi, 1986; Tabrizchi, 2001). In contrast, TPR did not change at the higher 
dose due to simultaneous increase in mean arterial pressure and cardiac output (lmms et 
a!., 1974; Pang & Tabrizchi, 1986; Tabrizchi, 2001). 
Noradrenaline significantly increases the heart rate in intact anaesthetized rats while it 
lowers the heart rate in rats treated with a ~-blocker (Imms et al., 1974; Pang & Tabrizchi, 
1986; Tabrizchi, 2001 ). Compensatory vagal reflex activity also slows the heart rate, 
overcoming the direct cardioaccelerating (increase of heart rate) action of noradrenaline 
(Young et a!., 1992; Westfall & Westfall, 2006). Administration of noradrenaline 
increased dP/dt in intact anaesthetized rat (Tabrizchi, 2001). Moreover, noradrenaline 
was found to increase both dP/dtmax and dP/dtmin in isolated perfused heart with constant 
preload and afterload indicating a rise in cardiac contractility (Geier et al., 2002). 
Haematocrit was found to increase during noradrenaline administration implying a 
decrease in plasma volume (Floyer & Morris, 1976; Aziz & Sommer, 1982). The 
explanation for the latter phenomenon is suggested to be that potent post-capillary 
vasoconstriction elicited by noradrenaline increases the filtration pressure and mobilizes 
the fluid out of the vessel (Floyer & Morris, 1976; Aziz & Sommer, 1982). In addition, 
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noradren~line significantly increases the Pmcf but has limited effect on right atrial 
pressure (Pang & Tabrizchi, 1986; Bower & Law, 1993; Tabrizchi, 2001). Therefore, 
the PGVR is elevated (Bower & Law, 1993). Simply put, total body venous tone was 
substantially elevated by the administration of noradrenaline. 
In summary, noradrenaline may either maintain or increase the cardiac output. The 
haemodynamic factors can change in the following manner: 1) TPR and resistance to 
venous return increases; 2) the whole heart pumping ability which is indicated by heart 
rate and cardiac contractility is elevated; 3) total body venous tone rises. The 
underlying mechanism for the cardiac output alteration is that the increase in both arterial 
resistance and resistance to venous return during noradrenaline administration tend to 
lower cardiac output, while the positive inotropic effect of noradrenaline and the increase 
of total body venous tone help to increase the cardiac output. At a moderate dose of 
noradrenaline, the level of driving force to increase cardiac output is balanced with that 
of lowering cardiac output; therefore the output of the heart is unchanged (Tabrizchi, 
2001 ). However, at the higher dose or in animals with suppressed autonomic regulation, 
the circulatory changes that favor cardiac output increase overwhelms the cardiac output 
lowering effect of other circulatory factors; as a result cardiac output is increased. 
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1.3. Haemodynamic effects of arginine vasopressin 
Arginine vasopressin (AVP), also known as antidiuretic hormone, is essential for both 
osmotic and cardiovascular homeostasis (Share, 1988). Two major physiological roles 
of the circulating AVP are 1) maintaining the arterial blood pressure when blood volume 
is decreased; and 2) protection of the plasma osmolality when plasma solute 
concentration is increased (Share, 1988). The different physiological effects of AVP are 
mediated via stimulation of the Vasopressin 1 (VI) receptor (or VI a, vascular), the 
Vasopressin 2 (V2) receptor (renal), the Vasopressin 3 (V3) receptor (or V1b, pituitary), 
the oxytocin receptor, and purinergic 2 receptor (P2R) (Holmes et a/., 2003). The 
antidiuretic effect of this peptide has been exploited clinically to treat diabetes· insipidus 
for over half a century (Holmes et al., 2003). Recently, it was found that plasma AVP 
was inappropriately low in advanced vasodilatory septic shock and exogenous AVP 
infusion increased and maintained blood pressure and reduced the use of catecholamine 
in such population of patients (Landry et al., 1997). Therefore, this rationale has been 
the basis for the use of AVP in the treatment of septic shock. However, limited 
controlled clinical trials are available on the effectiveness, efficacy, and safety of the use 
of AVP for treatment of patients with shock (Holmes & Russell, 2004). For this reason, 
it is not recommended that AVP be used as a first-line or routine therapy in patient with 
septic shock (Holmes & Russell, 2004). 
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Reduction of cardiac output has long been observed in subjects when AVP is 
administered (Share, 1988). In ganglion-blocked conscious rats as well as anaesthetized 
rats, cardiac output was decreased during the infusion of AVP (Share, 1988; Hernandez et 
a/., 1991; Tabrizchi & Ford, 2004). ·When AVP is administered and its plasma 
concentration is maintained within the physiological level (2.0 fmol/ml compared with 
1 ~ 9 fmollml in control dogs), TPR increases and cardiac output decreases (Montani et al., 
1980; Tipayamontri et a!., 1987). The increase in vascular resistance is most prominent 
in stomach, small and large intestines, muscles, and skin vascular beds (Charocopos et al., 
1982). However, the mean arterial pressure does not change due to the baroreflex (Ohta 
et al., 1991). It is suggested that the reduction of cardiac output is mediated centrally 
while the elevation of TPR is due to the vasoconstrictor effects of AVP through the V1 
receptor (Montani et a!., 1980; Ohta et a/., 1991 ). At pharmacological dose levels, AVP 
has been shown to increase the mean . arterial pressure, the arterial resistance and the 
resistance to venous return in a dose dependent manner (Walker, 1986; Lee et al., 1988; 
Martin & McNeill, 1990; Hernandez et al., 1991; Hernandez et al., 1994; Tabrizchi & 
Ford, 2004). 
In conscious rats, heart rate was dose dependently decreased following infusion of AVP 
(Hernandez et a!., 1991; Hernandez et al., 1994 ). In contrast, the peptide exerts no 
effect on the heart rate in ganglion-blocked conscious rats and anaesthetized rats 
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(Hernandez et al., 1991; Tabrizchi & Ford, 2004). The reduction of the heart rate is 
believed to be mediated both by the neurogenic mechanism and the decrease in coronary 
blood flow (Share, 1988; Hernandez et al., 1994). When coronary perfusion is kept 
constant, the contractility of isolated rat heart displays biphasic reaction to AVP infusion: 
while dP/dtmax increased at the lower concentrations (50 and 100 pg/ml) it decreased at 
higher concentration of 400 and 500 pg/ml infusion (Walker et al., 1988). It is 
suggested that the direct cardiac effects of AVP were mediated by the V 1 receptor. In 
vivo, AVP infusion significantly increased dP/dt compared to corresponding saline values 
(Tabrizchi & Ford, 2004). It has been known that when both preload and afterload are 
kept constant, an increase in dP/dt means an increment in cardiac contractility. 
However, during AVP administration, afterload increases with limited effects on preload. 
Therefore, the elevation of dP/dt may be due to an increase of afterload or positive 
inotropic effects or both (Lee eta!., 1988; Tabrizchi & Ford, 2004). 
AVP has limited effects on P mcf and central venous pressure when infused acutely, 
therefore the PGVR was found to be unaffected (Trippodo, 1981; Pang & Tabrizchi, 1986; 
Tipayamontri et al., 1987; Share, 1988; Lee eta!., 1988; Hernandez eta!., 1991; Ohta et 
al., 1991; Hernandez et al., 1994; Tabrizchi & Ford, 2004). This is because AVP has 
less constrictor effects on veins compared to arteries (Trippodo, 1981 ). However, 
Tipayamontri et al. (1987) reported that chronic AVP infusion (2.6 ng/kg/min, 50 ml each 
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day for ~ days) reduced Pmcf· It was stipulated that suppression of renin-angiotensin 
system and/or sympathetic nervous system was responsible for the effects of AVP in 
reducing Pmcf (Tipayamontri eta!., 1987). Acute infusion of AVP (1, 3, 10 ng/kg/min 
for 20 min) has no significant impact on the total blood volume and unstressed blood 
volume in intact anaesthetized animals (Lee et al., 1988; Tabrizchi & Ford, 2004). As 
well, the haematocrit did not change significantly in rats in the latter experiments 
(Hernandez et al., 1994; Tabrizchi & Ford, 2004). Therefore, the total body venous 
tone did not change during short term AVP infusion (Lee et al., 1988; Martin & McNeill, 
1990). Nevertheless, Floyer and Morris (1976) reported a decrease in haematocrit 
during AVP infusion (60 J..llU/min in 0.15 M-NaCl) indicating an increase in plasma 
volume in female Wistar rats (Floyer & Morris, 1976). The kidneys were suggested to 
play an important role in the reduction in haematocrit because the latter phenomon 
disappeared in nephrectomized rats (Floyer & Morris, 1976). The source of plasma 
expansion is suggested to derive from the interstitial space (Floyer & Morris, 1976). 
The discrepancies on haematocrit alteration may be due to the way that AVP and animals 
were prepared, different doses as well as species differences. Simply, the total body 
venous tone may not change or increase during infusion of AVP. 
In summary, AVP administration decreases cardiac output, and the haemodynamic 
parameters change in the following ways: 1) TPR increases; 2) heart rate decreases and 
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cardiac contractility may either increase or decrease; and 3) total body venous tone 
remains unchanged or increases. The reduction in cardiac output is most likely due to 
an inadequate venous return and a failure of the left ventricle to overcome the increase in 
afterload (Hernandez et al., 1991 ). Inadequate venous return is the result of no change 
in PGVR and increased resistance to venous return. The elevated afterload signifies the 
increase in TPR. This situation is also referred to as cardiac preload-afterload mismatch 
(Hernandez et al., 1994 ). In addition, supraphysiological dose of AVP may exert 
negative chronotropic and inotropic effects directly on the heart (Walker et a/., 1988). 
This also can be responsible for the reduction of cardiac output. Finally, it is also 
suggested that AVP may decrease cardiac output by baroreflex regulation (Montani et a/., 
1980). 
1. 4. Haemodynamic effects of sodium nitroprusside 
Sodium nitroprusside (SNP) is a nitrovasodilator that acts by releasing nitric oxide 
(Hoffman, 2006). Nitric oxide activates the guanylyl cyclase-cyclic GMP-cyclic 
GMP-dependent protein kinase pathway leading to vasodilation (Hoffman, 2006). SNP 
dilates both arterioles and venules, and the consequent haemodynamic effects result 
mainly from a combination of venous pooling and reduced arterial resistance (Hoffman, 
2006). It has been used for 1) rapid reduction of arterial pressure in the presence of 
hypertensive crisis regardless of etiology; 2) diminution of myocardial oxygen demand 
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by decre~sing afterload in the situation of low cardiac output when blood volume is 
normal or increased; and 3) reducing blood loss during operation (Friederich & 
Butterworth, 1995; Hoffman, 2006). Compared with other vasodilators, SNP offers the 
advantage of exquisitely precise dose titration for critically ill patients (Mills, 2003). 
However, the drug administration needs invasive monitoring and skilled nursing (Mills, 
2003). Moreover, cyanide toxicity also limits the clinical use of SNP for prolonged 
periods (Friederich & Butterworth, 1995; Hoffman, 2006). 
Administration of SNP has long been observed to decrease the cardiac output in subjects 
with· normal left ventricle function (Gmeiner et a/., 1975). In cats with suppressed 
autonomic reflexes and spontaneous respiratory movement, cardiac output was changed 
little by the infusion of SNP (Bower & Law, 1993). Similar results were also found in 
hexamethonium treated dogs (Ogilvie & Zborowska-Sluis, 1991). Increasing the dose 
of SNP results in progressive fall in. mean arterial pressure, TPR and resistance to venous 
return (D'Oyley et a/., 1989; Bower & Law, 1993 ). The reduction in resistance is 
linearly related to the logarithm of the SNP dose (correlation coefficients r > 0.73, P < 
0.01; SNP, 0.4 - 40 nmol/kg/min) (Bower & Law, 1993). In contrast, TPR and 
resistance to venous return was found unchanged during the treatment of SNP in 
pentobarbital anaesthetized, ganglion blocked, ventilated, and splenectomized dogs (SNP 
dose 1 llg/kg/min) (Ogilvie & Zborowska-Sluis, 1991 ). 
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Sodium nitroprusside dose-dependently increases the heart rate due to sympathetic reflex 
(D'Oyley et a/., 1989). In cats with suppressed autonomic reflexes, heart rate did not 
. alter significantly (Ogilvie & Zborowska-Sluis, 1991; Bower & Law, 1993). No direct 
positive chronotropic action of the drug has been observed in isolated rat heart (Gmeiner 
et al., 1975). As well, a wide range of SNP concentration (1-1000 ng/ml) did not alter 
dP/dtmax (Gmeiner et al., 1975). The effect ofSNP on Pmcris limited in conscious intact 
rats (D'Oyley et a/., 1989). P mcf was dose dependently decreased in ganglion blocked 
rats and cats (D'Oyley et al., 1989; Ogilvie & Zborowska-Sluis, 1991; Bower & Law, 
1993 ). The lack of change in P mcf in intact rats might be due to the compensatory neural 
reflex (D'Oyley et al., 1989). 
Simply put, SNP lowers the cardiac output in subjects with normal ventricular function. 
SNP 1) dose dependently decreases the TPR; 2) has no direct effects on the heart rate and 
cardiac contractility but induces tachycardia due to reflex sympathetic nerve activation; 
and 3) reduces total body venous tone in ganglion blocked animals but does not affect 
venous tone in intact animals. The reduction of cardiac output is caused by a fall in left 
ventricular filling pressure (Gmeiner et al., 1975). Also, SNP is able to pool blood in 
the capacitance vessels by relaxing systemic veins and thereby reducing venous return 
(Gmeiner et al., 1975). In ganglion-blocked animals, the substantial fall in Pmcf further 
decreases cardiac output by lowering the PGVR (Bower & Law, 1993). 
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1. 5. Haefr!odynamics in rat with arteriovenous fistula 
An arteriovenous fistula (AVF) is an abnormal direct passage between an artery and a 
vein (Holman, 1-965). It can be congenital or acquired (Holman, 1965). AVF 
generates a high output low TPR state that resembles the hyper-haemodynamic condition 
of several diseases such as vascular injury or congenital malformation, chronic severe 
anemia, severe hepatic or renal disorders, and septic shock (Anand & Florea, 2001). 
The effect of AVF on the haemodynamics of the circulation is mainly determined by the 
amount of blood diverting through it (Holman, 1940). 
The cardiac output increases immediately within the first two to three heart beats after 
the opening of a fistula in experimental dogs (Guyton & Sagawa, 1961 ). The increment 
in cardiac output is similar to the amount of fistula flow as long as the fistula flow 
remains less than 19% of the cardiac output prior to fistula creation (Frank et al., 1955~ 
Guyton & Sagawa, 1961 ). Thereafter, the cardiac output experiences an additional rise 
in the next 15-30 seconds in dogs with intact reflexes but not in the areflexic dogs 
(Guyton & Sagawa, 1961 ). Since there is limited change in the heart rate in short term 
AVE it is suggested that the augmentation in the cardiac output is mainly due to the 
increase in stroke volume. Once the shunt flow exceeds 27% of the control cardiac 
output, the increase in cardiac output will no longer compensate the fistula t1ow (Guyton 
& Sagawa, 1961 ). In such condition, the perfusion to tissues is compromised as there is 
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diminished blood flow in systemic circulation due to the diversion of blood flow through 
the fistula. The blood through the fistula repeatedly flows in the short circuit with high 
speed. Consequently, the systemic circulation has to increase the resistance to maintain 
the at1erial pressure (Frank et al., 1955). When the perfusion to tissues is compromised 
due to large AVF, infusion of isotonic saline will increase cardiac output dramatically 
(Frank eta/., 1955). Approximately, 88% of the elevated output is shown to be diverted 
to the systemic circulation with a decrease in the systemic resistance (Frank et al., 1955). 
The infusion of the isotonic saline returns the systemic flow to the level prior to fistula 
introduction in both areflexic and reflexic dogs (Guyton & Sagawa, 1961). Such 
evidence would suggest that the availability of blood volume for the venous return 
instead of the cardiac reserve is one limiting factor of the increase in cardiac output in 
acute uncompensated AVF (Frank eta!., 1955). In a rat model of chronic AVF in which 
the shunt flow varied from 52% to 77% of the cardiac output prior to fistula introduction, 
systemic flow decreased significantly compared with the cardiac output in rats without 
AVF 1 hour and 1 week after fistula creation (Huang et al., 1992). However, the 
systemic flow returned to the same level as in the rat without AVF at the fifth week 
(Huang et al., 1992). The recovery of the systemic flow at the fifth week was explained 
by compensatory increase in blood volume and heart hypertrophy (Huang eta/., 1992). 
Perhaps not surprisingly, the TPR is decreased immediately after the opening of the 
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fistula al}d it is maintained at the lower level as long as the fistula exists (Guyton & 
Sagawa, 1961). Although the mean arterial blood pressure decreases shortly after the 
opening of the fistula, it returns to the level just below the control level during the 
ensuing 30 seconds (Guyton & Sagawa, 1961). This return ofthe pressure is thought to 
be mediated by a neural reflex (Guyton & Sagawa, 1961). Huang et al. (1992) have 
shown that in rats with fistula the mean arterial pressure was reduced significantly in the 
first week but returned to the control level at the fifth week post-shunt. The underlying 
mechanism responsible for the restoration of the mean arterial pressure may involve 
blood volume expansion (Huang et al., 1992). 
Opening and closing AVF has limited effects on the heart rate in experimental dogs and 
rats (Nickerson et al., 1951a; Huang et al., 1992; Wang et al., 2003). Guyton & Sagawa 
(1961) reported an average increase of 13% in heart rate upon the opening of the fistula 
with variation of 0 to 87%. Similar results have been reported in rats (Liu et al., 1991 ). 
Flaim et al. (1979) however recorded significant reduction of the heart rate 2 months 
after creation of the AVF. A number of reasons may account for the contradictory 
findings which include 1) different species, 2) size of the fistula, and/or 3) different 
length of recovery following introduction of AVF (Flaim et al., 1979). 
In rats with chronic AVF, left ventricular function IS depressed as evidenced by a 
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reduction in left ventricular dP/dt and left ventricular systolic pressure, and an increase in 
the left ventricular end diastolic pressure (Liu et al., 1991; Wang et al., 2003 ). 
According to Wang et al. (2003), no changes in cardiac contractility were detected at the 
first, second, and fourth weeks following the introduction of AVF, but thereafter, a 
progressive decline in cardiac contractility was observed based on dP/dt values recorded. 
The right ventricular dP/dtmax, right ventricular systolic pressure and right ventricular end 
diastolic pressure are all found to be significantly increased at both 1 week and 1 month 
after creation of fistula (Liu et al., 1991 ). In isolated rat heart, the deviation of these 
haemodynamic values from the norm occurs earlier ( 4 vs 8 week) and is more dramatic 
compared with those from intact rats (Wang et a/., 2003). This can perhaps be best 
explained by the existence of compensatory mechanism in vivo (Wang et a/., 2003 ). 
In experimental dogs, total blood volume is increased several weeks after creation of 
AVF (Epstein & Ferguson, 1955). This is accompanied by an increase in plasma 
volume but not the total red cell volume (Epstein & Ferguson, 1955; Gratama et al., 
1992). There is a positive correlation between the increase in plasma volume and the 
magnitude of the fistula flow (r = 0.81, P < 0.01) (Gratama et a/., 1992). Renal 
retention of salt and water stimulated by reduced renal flow is believed to be the 
contributory factor for the volume expansion (Hilton et al., 1955; Gratama et al., 1992). 
In addition, the amount of intravascular protein is found to be significantly higher in 
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lambs with AVF (5.0 +/- 0.3 vs. 3.5 +/- 0.2 g/kg body mass, P < 0.001) (Gratama et al., 
1992). The increased amount of intravascular protein provide oncotic pressure to retain 
fluid in the vascular compartment (Gratama eta/., 1992). The latter fact may be another 
mechanism responsible for the plasma volume expansion (Gratama eta/., 1992). 
Once the fistula is introduced, an additional volume of blood leaks into the venous side. 
This is believed to be the contributory factor to increase PGVR. When the size of the 
fistula is relatively small, that is, the volume of the blood diverting through it is less than 
19% of control cardiac output, the increase in venous return to the right heart equals that 
of the fistula flow (Warren et al., 1951 ). According to the Frank-Starling mechanism, 
the heart pumps out the extra venous return to prevent the reduction of the systemic flow. 
If the size of the fistula further enlarges, there will not be sufficient blood supply for the 
pumping heart (Wan·en et al., 1951 ). The flow to the systemic organs is then reduced 
and shunted to the venous side through fistula. According to Guyton et al. (1973e), the 
venous return is almost directly proportional to the PGVR as long as the resistance ofthe 
circulation remains constant. In dogs, Pmcf is significantly increased upon opening of 
the fistula due to the sympathetic nerve activation (Guyton & Sagawa, 1961 ). Opening 
of the fistula also has a slight net increase in right atrial pressure (Guyton & Sagawa, 
1961 ). However. other researchers did not find any change in the atrial pressure 
(Nickerson et al., 1951 b). The variation of the fistula size might explain the different 
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observations regarding changes in the atrial pressure. In conclusion, AVF increases 
venous return due to the rise of PGVR. 
In summary, a high cardiac output state is generated by the existence of AVF. In such 
hyper-haemodynamic condition, 1) TPR decreases; 2) heart rate and cardiac contractility 
do not change significantly in acute AVF but cardiac function exhausts in the chronic 
state; 3) a simultaneous increase occurs in Pmcf and total blood volume. The 
augmentation of cardiac output is caused by a decrease in TPR and an increase in PGVR. 
Blood volume expansion also contributes to the elevation of cardiac output in chronic 
AVF. 
1:6. Nature ofthe Problem 
Although the pathophysiology of AVF on the circulatory system has been well described, 
very few pharmacological studies have been conducted to document the effect of 
vasoactive agents in this paradigm. 
It has been reported that intravenous administration of 1 Jlglkg of noradrenaline increased 
cardiac output in dogs with AVF (Nakano, 1968). This dose of noradrenaline decreased 
heart rate by 20 beats/min following an initial increase of 12 beats/min. (Nakano, 1968). 
As well it increased mean arterial pressure, shunt flow, and systemic flow (Nakano, 
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1968). ,Sympathomimetics such as adrenaline was found to increase cardiac output, 
systemic flow, fistula flow, and heart rate in volume overload dogs (Nakano, 1968). 
Also, adrenaline increases the arterial pressure due to increases in cardiac output and 
TPR in the same animal model (Nakano, 1968). 
In conscious dogs with AVF, intravenous infusion of SNP at 1.2 J.Lg/kg/min decreased left 
ventricular end diastolic pressure without any significant change in left ventricular end 
diastolic dimension or left ventricular dP/dtmax (O'Rourke et a/., 1982). A dose of 1.8 
J..Lg/kg/min SNP seemed to further decrease left ventricular end diastolic pressure, left 
ventricular systolic pressure and aortic pressure (O'Rourke et a/., 1982). A fall in left 
ventricular end diastolic dimension and an increase in left ventricular dP/dtmax also 
occurs during administration of SNP (O'Rourke et a/., 1982). The reduction in the left 
ventricular filling pressure was suggested to be the result of the reduced venous return 
due to venodilation (O'Rourke et a/., 1982). The rise in left ventricular dP/dtmax at the 
·dose of 1.8 J..Lg/kg/min may be caused in part by baroreceptor reflex activation because 
the elevation of dP/dtmax disappeared following the treatment with a beta blocker 
(O'Rourke eta/., 1982). 
Nitroglycerin (30 J..Lg/kg ) and bradykinin increased cardiac output, systemic flow while 
reducing fistula flow, heart rate and arterial pressure in dog with large AVF (Nakano, 
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1968). Consistently, in the rat model of chronic AVF (6.4 months), cardiac output was 
not altered by nitroglycerin infusion at 32 )lglkg but decreased significantly at 2 and 8 
)lg/kg (Flaim, 1982). In the latter study, there was a significant increase in systemic 
vascular resistance while the mean arterial pressure and central venous pressure did not 
change (Flaim, 1982). The vasodilating effect of nitroglycerin may be masked by the 
increased sympathetic tone to maintain the blood pressure (Flaim, 1982). In contrast, 
nitroglycerin (8 )lg/kg) did not significantly increase cardiac output due to reduced 
systemic vascular resistance in acute AVF rats (20· days). The contradictory results of 
the systemic vascular resistance response in acute vs. chronic AVF rats to nitroglycerin 
might be that both fistula and nitroglycerin is tending to reduce vascular resistance but 
the sympathetic activation was not sufficient enough to overcome the resistance lowering 
effect from both of them (Flaim et a/., 1981 ). In chronic AVF, blood volume expansion 
and venous return elevation compensated the low resistance caused by AVF and return 
blood pressure and sympathetic tone tp normal. Therefore: vascular resistance was 
increased by reflex activation of sympathetic nervous system during nitroglycerin 
infusion in animals with chronic AVF. 
Isoproterenol which is a hypotensive agent in normal dogs increased arterial pressure in 
fistula dogs by enhancing cardiac output and increasing systemic flow, fistula flow, heart 
rate, myocardial contractility, and venous return while reducing TPR (Nakano, 1968). It 
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is sugge~ted that flow through the fistula is always positively related to systemic arterial 
pressure but is not influenced by changes in either systemic blood flow or cardiac 
contractility (Nakano, 1968). In addition, it is reported that transdermal glyceryl 
trinitrite increased the blood flow through the surgically generated fistula in patients 
receiving haemodialysis therapy (Akin et al., 2002). 
1. 7. Objectives 
A working hypothesis for the study based on Guyton's theory of cardiac output 
regulation (Guyton, 1981) would predict infusion of noradrenaline will increase cardiac 
output by enhancing heart pumping performance and increasing venous return which 
overcomes the elevation of TPR; AVP would be expected to decrease cardiac output due 
to increment in TPR without any change in venous return; and SNP to a) increase cardiac 
output by decreasing TPR; b) decrease cardiac output by reducing venous return; or c) 
maintain the cardiac output by simultaneous reduction of TPR and elevation of venous 
return. In the latter cases, cardiac output decreases whenever resistance to venous 
return increases. However, Guyton's logic was based on experimental data from normal 
animals. In such a condition as chronic AVF, lack of venous return is not a limiting 
factor to control cardiac output anymore. On the contrary, the blood flow from the 
venous side is at a relative high level and drives the heart to pump super-normally 
according to the Frank-Starling mechanism. To pump all the venous return becomes the 
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dominant factor of cardiac output regulation before the heart fails. The other point that 
does not occur in Guyton's experimental animal is that the TPR is set at a very low level 
due to the existence of fistula. According to Ohm's law no matter how strong an effect 
of vasoactive agents on the systemic vessels, the resistive load against the pumping heart 
will not change as much as in animals without fistula. Since the situation we were 
dealing with is totally different from which Guyton's theory was based on, we may 
expect different results. Therefore, the aim of the present study was to investigate how 
cardiac output and other circulatory factors alter during the administration of vasoactive 
agents. 
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2. Mater,ials and Methods 
2.1. Preparation of animals with arteriovenous fistula 
We have adopted the method described by Garcia and Diebold (1990) for the 
introduction of a shunt between abdominal aorta and inferior vena cava by inserting a 
20-gauge needle from the abdominal aorta into inferior vena cava in order to create the 
arteriovenous shunt. Briefly, 24 male Sprague-Dawley rats (230-250 g) were 
anaesthetized with halothane (induction with 7.5% halothane in 100% oxygen; 
maintenance with 1.5% halothane in 100% oxygen). Before surgery, the animals were 
heparinized (100 IU/ml/kg) by injecting heparin subcutaneously. A laparotomy was 
performed and both vena cava and abdominal aorta were exposed. At positions qmdal 
to the renal arteries and cephalic to the aortic bifurcation, two vascular clamps were 
placed on both vena cava and abdominal aorta. Subsequently, the aorta was punctured 
with a 20 gauge disposable needle (Becton-Dickinson, Franklin Lakes, NJ) at the place 
two thirds caudal to the renal artery and one third cephalic to the aortic bifurcation 
(Garcia & Diebold, 1990; Huang et al., 1994). Then the needle was forwarded into the 
aorta, perforating its adjacent wall and penetrating the vena cava. The needle was 
shaken mildly to make sure the hole was big enough for a patent fistula. Thereafter, the 
needle was fully withdrawn and the hole on the aorta was repaired with one 6-0 vascular 
suture (Prolene, Johnson & Johnson, Somerville, NJ). The vascular clamps were 
removed 30 s after completion of the anastomosis. The whole process of circulation 
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cessation was less than 5 minutes. The patency of the fistula was verified visually by 1) 
swelling of the vena cava; 2) the mixing of the bright arterial blood with dark venous 
blood. Subsequently, the internal abdominal wall was closed with absorbable suture 
(Surgigut, Norwalk, CT). The skin cut was closed by single stitches with silk (3-0). 
Each animal was allowed to recover for five weeks. For 8 sham-operated rats, the 
needle was inserted into the abdominal aorta but not pushed into the inferior vena cava. 
Following this surgical procedure, each animal was treated with an analgesic, 
buprenorphine (0.5 mg/kg s.c.; q12 hr for 48 hr). 
2. 2. Surgical preparation 
Under halothane anesthesia (induction with 7.5% halothane in 100% oxygen; 
maintenance with 1.5% halothane in 100% oxygen), catheters (polyethylene tubing; I.D. 
0.58 mm, O.D. 0.965 mm) were inserted into the left iliac artery and vein. The left 
venous tube was advanced into the inferior vena cava for the measurement of central 
venous pressure. The arterial line was for continuously recording of mean arterial 
pressure. Subsequently, sodium pentobarbitone (65 mg/kg) was injected slowly through 
the venous line with close monitoring of the arterial pressure as halothane was reduced 
and ceased. Thereafter, two catheters were put into the right iliac artery and vein for 
blood sample withdrawal and drug/vehicle administration respectively. In addition, a 
catheter was advanced into the left ventricle via the right carotid artery for measurement 
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of left ventricular pressure (Schenk et al., 1992) and injection of radioactive-labeled 
microspheres. A saline-filled balloon-tipped catheter was advanced into the right atrium 
through the right external jugular vein. Inflation of the balloon transiently stops the 
circulation and the cessation of circulation is necessary for the P mcf measurement (Pang 
& Tabrizchi, 1986). Afterward, a laparotomy was performed and the abdominal aorta 
and inferior vena cava were exposed. A transit sonic flow probe was placed on the 
aorta cephalic to the fistula. The blood flow in the aorta above fistula is regarded as an 
index of flow through the fistula. Finally, the abdominal cavity was closed. All 
catheters were filled with heparinised (25 IU/ml) normal saline (0.9% NaCl). The 
animals were tracheotomized and allowed to stabilize for 1 hr when arterial pressure, 
venous pressure, ventricular pressure, fistula flow index and heart rate were monitored 
continuously. Body temperature was maintained at 37 ± I °C using a heating lamp and 
monitored with a rectal thermometer. Arterial blood pressure and central venous 
pressure were recorded with a pressure transducer (Gould Statham, USA; Model PD23B). 
The pressure transducer was connected to an amplifier (DA 1 OOA) that in turn was linked 
to a universal interface module (UIM 1 00). Meanwhile, the interface module was 
interfaced with an acquisition unit (MP 1 00) (Tabrizchi, 2001 ). The data was collected 
using AcqKnowledge ill system. Heart rate and dP/dt were calculated from the blood 
pressure and left ventricular pressure signal, respectively, with the aid of AcqKnowledge 
ill system (Tabrizchi, 2001 ). 
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2. 3. Measurement of cardiac output 
This technique has been described in detail elsewhere (Pang, 1983; Tabrizchi & Pugsley, 
2000). Briefly, suspensions of micro-spheres (Mandel, Ontario, Canada; 15 11m 
diameter) labelled with 57Co (20,000 - 22,000 in 150 111) were injected into the left 
ventricle over a period of 10 s. Blood was withdrawn from the right femoral artery at 
the rate of 0.35 ml/min starting 15 s before microsphere injection using an 
infusion/withdrawal pump (Kd Scientific, Holliston, MA, USA; Model 120) for 1 min. 
The blood sample and syringes used for injection ofmicrospheres or withdrawal ofblood 
were counted for radioactivity at 80- 160 keV using a dual channel automatic gamma 
counter (Clinic Gamma Counter, LKB Wallac, Gaithersburg, MD, USA; Model 1272). 
The withdrawn blood sample was slowly injected back into the animals immediately 
after counting radioactivity. 
2. 4. Measurement of mean circulatory filling pressure 
The technique ofPmcrmeasurement developed by Yamamoto et al. (1980) was employed 
in the present study. In detail (Yamamoto et al., 1980; Pang & Tabrizchi, 1986), by 
injecting a small volume of fluid into the balloon, which was pre-positioned in the right 
atrium, for a period of 5-7 s, the blood flow through the right atrium was stopped. As a 
consequence, the circulation was arrested completely. Right after the balloon inflation, 
mean arterial pressure decreased and central venous pressure increased simultaneously. 
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Both pressures reached plateau levels within 4-5 s which are referred to as final arterial 
pressure (FAP) and venous plateau pressure (VPP) respectively. 
2: 5. Measurement of blood volume 
Plasma volume (PLV) and total blood volume (TBV) were determined according to 
Migita et al. (1997) using Evans blue. A 100-fll-blood sample was collected in two 
heparinised capillary tubes, before and after the administration of Evans blue dye (5 
mg/kg). The samples were centrifuged for 3 min to obtain haematocrit values. A 
50-fll sample of plasma was collected from haematocrit tubes and diluted 1 :20 in normal 
saline. The absorbance was recorded using a 4050 UV Nisible spectrophotometer (LKB 
Biochrom, Cambridge, UK) at 620 nm (A620) and was corrected first for the presence of 
haemoglobin at A 620 (blank), and then for turbidity at A740· PLV was determined by the 
equation PLV = (C X Vi)/Cr; where C and Vi are the concentration and volume, 
respectively, of Evans blue dye that was injected and Cp is the plasma concentration of 
Evans blue dye. A plasma trapping factor (tp) of 0.96 and total body-to-venous 
haematocrit (Hct) ratio (Fcens) of 0.74 were employed (Migita et al., 1997) to estimate 
TBV using the equation, TBV = PLV/1- (HctXtpXFcens). 
2. 6. Measurement of the organ weight 
After completion of each experiment and under anaesthesia, the rat was euthanized by 
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opening the chest. Heart, lung, and both kidneys were excised and removed. Right 
ventricle and left ventricle plus septum were separated. Fat tissue and fascia were 
removed carefully. The weights of the organs were recorded. The lungs were put into 
the oven (50 °C) for 6 hrs and the dry weight was also recorded. 
2. 7. Experimental designs and protocols 
After the surgery of AVF introduction, the body weight was recorded every day. The 
weights were compared between shunted and sham-operated groups. The existence of 
AVF was proved by a higher fistula flow index which is the flow in the abdominal aorta 
cephalic to the fistula. Five weeks after the introduction of AVF, shunted rats were 
randomly assigned to four groups (n = 5-7). There are 8 sham-operated rats working as 
control group. After surgical preparation, animals were stabilized for 1 hr when arterial 
pressure, venous pressure, ventricular pressure, fistula flow index and heart rate were 
monitored continuously. Subsequently, they were infused with one of the following 
solutions: saline (0.9% NaCl; 0.002, 0.006 and 0.02 ml/kg/min), noradrenaline (1, 3, 10 
Jlg/kg/min), AVP (10, 30, 100 ng/kg/min), or SNP (100, 300, 1000 ng/kg/min) 
respectively at three increasing doses. The duration of each infusion at each dose was 
18-20 min. Two sets of control measurement which constitutes of cardiac output and 
P mcf measurements and 1 00-Jll-blood sample were taken prior to administration of 
saline/drug and another three sets of measurements were repeated during the saline/drug 
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administration. An additional group (n=8) that was composed of sham-operated rats 
was infused with saline at the rate of 0.002, 0.006 and 0.02 ml/kg/min. 
2. 8. Chemicals 
All drugs were made up fresh daily and dissolved in normal saline (0.9% NaCI). 
Noradrenaline was purchased from Sigma Chemical Company (StLouis, MO, U.S.A.), 
AVP from Sigma Chemical Company (Ontario, Canada), and SNP from Research 
Biochemicals International (Natick, MA, U.S.A.). 
2. 9. Calculations and statistical analysis 
Cardiac output (ml/min) was calculated as the rate of withdrawal of blood multiplied by 
the total injected cpm divided by cpm in withdrawn blood; systemic flow (ml/min) was 
calculated as cardiac output divided by fistula flow index. CI is cardiac output per 100 
g body weight, systemic flow index is systemic flow per 100 g body weight, and fistula 
flow index is fistula flow per 100 g body weight. P mer (mmHg) was calculated as the 
one sixtieth of difference between final arterial pressure and venous plateau pressure plus 
venous plateau pressure (Samar & Coleman, 1978; Yamamoto et al., 1980). Resistance 
to venous return (mmHg X min/ml) was calculated as the difference ofPmcrand central 
venous pressure divided by cardiac output (Bower & Law, 1993), and arterial resistance 
(mmHg X minlml) was obtained by dividing blood pressure by cardiac output 
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(Tabrizcqi & Ford, 2004); systemic resistance (mmHg X min/ml) was calculated by 
blood pressure divided by the difference between cardiac output and fistula flow; 
resistance of fistula (mmHg X min/ml) was calculated as the difference of blood 
pressure and central venous pressure divided by cardiac output. 
A correction was applied in calculating plasma volume and total blood volume over time 
using Evans blue dye. Evans blue dye is known to be eliminated from systemic 
circulation over time (El Sayed et a!., 1995). In two groups of experiments using sham 
operated rats (n=21) and fistula rats (n=32), we determined the elimination rate constant 
(k) for Evans blue. Thiobutabarbital anaesthetized rats were injected with Evans blue 
dye (5 mg/kg) and plasma concentration ofthe dye was determined over a course of2 hr 
(at 2, 60, 90, 120 min). A plot of Log [Evans blue dye] in plasma against time indicated 
first order elimination kinetics ( C = C0 e- k1), and the information from the plot were 
employed to calculate k and half life (1112) of Evans blue in plasma in rats. Assuming a 
two-compartment model, the calculated k for Evans blue dye were 0.3429 ± 0.0168 and 
0.192 ± 0.0135 (mean± SEM; n = 21) for a and~ respectively in sham-operated rats and 
0.2912 ± 0.0209 and 0.1791 ± 0.0132 (mean± SEM; n = 32) for a and~ respectively in 
fistula rats. The mentioned k values were used to correct for concentration of the dye in 
plasma over time in our study, and thus in calculating plasma volume and total blood 
volume. 
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All data are presented as mean ± standard error mean. Analysis of variance with 
repeated measures was used for comparison between haemodynamic values. In all 
cases, a probability of error less than 0.05 was selected as the criterion for statistical 
significance. 
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3. Results 
3.1. Haemodynamics in rats with chronic AVF 
There was no difference between the daily body weights of rats with AVF and 
sham-operated rats (Figure 1). The control value of CI of rats with chronic AVF was 
36.65 ± 2.28 ml/min per 100 g (mean ± SEM; n = 24) in comparison to 20.04 ± 0.86 
ml/min per 100 g in sham-operated rats (mean± SEM; n = 8) (Table 1 ). The value was 
82.9% higher than the mean CI of sham-operated rats. In rats with chronic AVF, blood 
pressure, pulse pressure and venous pressure were not significantly changed from 
sham-operated rats (Table 2). Both TPR and resistance to venous return decreased 
significantly in rats with chronic AVF compared to sham-operated rats (Table 3). Heart 
rate was not significantly altered in rats with chronic AVF and dP/dt was found to be at 
the same level when compared to the respective value in sham-operated group (Table 1 ). 
The fistula flow index (i.e. blood flow in abdominal aorta just below the renal artery) and 
Pmcf were significantly higher in AVF group than the respective values in sham-operated 
group (Table 1, 2). 
3.2 Haemodynamic effects of noradrenaline in rats with chronic AVF 
The baseline values are given in Table 4. All three doses of noradrenaline 
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Table 1. Cardiac index (CI; ml/min per 100 g), fistula flow index (FFI; ml/min per 
100 g), heart rate (HR; beat/min) and dP/dt (mmHg/sec) in thiobutabarbital 
anaesthetized rats with chronic arteriovenous fistula (n = 6; 5 weeks post shunt) and 
sham-operated rats (n = 8) infused with saline (C, control measurement; Ml, 
measurement 1 during the fist dose of infusion; M2, measurement 2 during the 
second dose of infusion; M3, measurement 3 during the third dose of infusion). 
The duration of each infusion was 18-20 min. Each value represents mean± SEM. 
CI FFI HR dP/dt 
c 36.65 ± 2.28* 24.97 ± 3.44* 339 ±II 6277 ± 362 
MI 36.96 ± 3.33* 25.28 ± 3.38* 342 ± I6 6I69 ± 483 
Fistula 
M2 36.11 ± 2.46* 23.85 ± 3.24* 345 ± 9 6II7±4I4 
M3 36.81 ± 3.58* 22.89 ± 3.55* 346 ± I2 6099 ± 348 
c 20.04 ± 0.86 2.03 ± 0.40 333 ±II 6373±35I 
M1 21.32 ± 1.05 1.87 ± 0.37 3I8 ± 2I 6445 ± 5IO 
Sham 
M2 20.09 ± 0.75 1.85 ± 0.33 3I8±16 6556 ± 507 
M3 20.21 ± 0.95 1.87 ± 0.32 309 ± I4 6282 ± 430 
*Significant different from respective value in sham-operated group; P < 0.05 
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Table 2. Blood pressure (BP; mmHg), pulse pressure (Pulse P; mmHg), venous 
pressure' (VP; mmHg), and mean circulatory filling pressure (P mcf; mmHg) in 
thiobutabarbital anaesthetized rats with chronic arteriovenous fistula (n = 6; 5 weeks 
post shunt) and sham-operated rats (n = 8) infused with, saline (C, control . 
measurement; M1, measurement 1 during the first dose of infusion; M2, 
measurement 2 during the second dose of infusion; M3, measuremenJ 3 during the 
third dose of infusion). The duration of each infusion was 18-20 min. Each value 
represents mean ± SEM. 
BP Pulse P VP Pmcf 
c 97.17±5.44 93.00 ± 9.93 2.15 ± 0.37 7.04 ± 0.50* 
MI 96.00 ± 6.17 93.17± 11.26 2.14± 0.39 6.88 ± 0.49* 
Fistula 
M2 94.17±6.01 94.33 ± 11.48 2.10±0.38 6.66 ± 0.36* 
M3 94.83 ± 5.71 99.67 ± 12.59 2.02 ± 0.48 7.09 ± 0.38* 
c 104.9 ± 5.00 77.88 ± 7.94 1.27±0.18 5.05 ± 0.14 
Ml 105.9 ± 7.87 77.13 ± 7.47 1.29±0.17 5.09 ± 0.21 
Sham 
M2 110.0 ± 8.60 82.13 ± 6.66 1.19 ± 0.16 4.96 ± 0.18 
M3 I 09.25 ± 8.69 81.13 ± 8.18 1.13 ± 0.16 4.92 ± 0.18 
*Significant different from the respective value in sham-operated group; P < 0.05 
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Table 3. Total peripheral resistance (TPR; mmHg x min per ml) and resistance to 
venous re,turn (RVR; mmHg x min per ml) in thiobutabarbital anaesthetized rats 
with chronic arteriovenous fistula (n = 6; 5 weeks post shunt) and sham-operated 
rats (n = 8) infused with saline (C, control measurement; Ml, measurement 1 during 
the first dose of infusion; M2, measurement 2 during the second dose of infusion; 
M3, measurement 3 during the third dose of infusion). The duration of each 
infusion was 18-20 min. Each value represents mean ± SEM. 
TPR RVR 
c 0.5847 ± 0.038* o.0274 ± 2.83 x 1 o-3* 
M1 0.5710 ± 0.081 * 0.0273 ± 3.94 X 10"3* 
Fistula 
M2 0.5535 ± 0.051 * 0.0262 ± 1.56 x10"3* 
M3 0.5697 ± 0.077* o.0287 ± 2.21 x 1 o-3* 
c 1.1587 ± 0.063 o.o420 ± 3.23 x w-3 
M1 1.1219 ± 0.125 0.0401 ± 3.58 x10"3 
Sham 
M2 1.1639 ± 0.084 0.0412±2.27 x10"3 
M3 1.2140 ± 0.126 0.0416±2.54 x1Q"3 
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Table 4. Baseline values of cardiac index (CI; mVmin per 100 g), fistula flow index 
(FFI; mVmin per 100 g), systemic flow index (SFI; mVmin per 100 g), blood pressure 
(BP; mmHg), pulse pressure (Pulse P; mmHg), venous pressure (VP; mmHg), mean 
circulatory filling pressure (P mer; mmHg), heart rate (HR; beat/min), dP/dt 
(mmHglsec), total peripheral resistance (TPR; mmHg x min per ml), resistance to 
venous return (RVR; mmHg x min per ml), systemic resistance (Syst R; mmHg x 
min per ml), and resistance of fistula (Rnstula; mmHg x min per ml) before 
administration of noradrenaline (NA; n = 7); arginine vasopressin (A VP; n = 5); 
sodium nitroprusside (SNP; n = 6); saline (n = 6) in thiobutabarbital anaesthetized 
rats with chronic arteriovenous fistula (5 weeks post shunt). Each value represents 
mean± SEM. 
NA AVP SNP Saline 
CI 38.04 ± 2.37 41.62 ± 3.32 39.36 ± 1.90 40.12 ±4.09 
FFI 21.74±2.13 21.48 ± 3.05 23.13±2.78 27.41 ± 3.88 
SF! 16.28 ± 1.49 15.84 ± 2.30 20.43 ± 1.19 15.72 ± 1.96 
BP 101.3 ± 5.93 96.8 ± 2.60 102.5 ±3.94 102.2 ± 5.12 
Pulse P 92 ± 5.5 104 ± 8.2 105 ± 11.5 99.0 ± 10.85 
VP 1.76 ± 0.33 1.72 ± 0.53 2.17±0.45 1.66 ± 0.28 
Pmcf 6.28 ± 0.36 6.64 ± 0.45 6.72 ± 0.35 7.22 ± 0.46 
HR 340 ± 11.5 292 ± 4.9 332 ± 12.4 354 ± 11.4 
dP/dt 6407 ± 315 6443 ± 252 6651 ± 302 6700 ± 230 
TPR 0.5791 ± 0.0755 0.6640 ± 0.0769 0.4977 ± 0.0346 0.5772 ± 0.0412 
RVR 0.0252 ± 2x I o·3 0.0307 ± 4x 1 0"3 0.0230 ± 3x10"3 0.0299 ± 2x 1 0"3 
Syst R 1.1955 ± 0.0853 1.4808 ± 0.2330 1.0659 ± 0.0735 1.4283 ± 0.114 
Rfistula 1.0640 ± 0.1903 1.0815 ± 0.1959 0.9628 ± 0.1011 0.8384 ± 0.1122 
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Figure 1 Daily body weight of rats with chronic arteriovenous fistula and 
sham-operated rats. Data represents mean value± SEM. 
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Figure 2 Percent change in cardiac index during administration of argmme 
vasopressin (AVP; 10, 30, 100 ng/kg/min), sodium nitroprusside (SNP; 100, 300, 
1000 ng/kg/min), noradrenaline (NA; 1, 3, 10 J.lg/kg/min), and saline (0.002, 0.006, 
0.02 ml/min) in thiobutabarbital anaethetized rats with chronic arteriovenous 
fistula (5 weeks post shunt). C, control; D1, dose 1; D2, dose 2; D3, dose 3. The 
duration of each infusion was 18-20 min. Data represents mean value ± SEM. 
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Figure 3 Percent change in systemic flow index during administration of arginine 
vasopressin (AVP; 10, 30, 100 ng/kg/min), sodium nitroprusside (SNP; 100, 300, 
1000 ng/kg/min), noradrenaline (NA; 1, 3, 10 Jlg/kg/min), and saline (0.002, 0.006, 
0.02 ml/min) in thiobutabarbital anaethetized rats with chronic arteriovenous 
fistula (5 weeks post shunt). C, control; D1, dose 1; D2, dose 2; D3, dose 3. The 
duration of each infusion was 18-20 min. Data represents mean value ± SEM. 
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(1, 3, 10 ,l..tg/kg/min) did not significantly change CI and systemic flow index in rats with 
chronic AVF when compared to both baseline level and respective values in saline treated 
rats (Figure 2, 3). Fistula flow index was significantly increased compared to both 
baseline level and respective values in saline treated rats by all three doses of 
noradrenaline administration (Figure 4). As well, blood pressure was significantly 
increased by all three doses compared to both baseline level and respective values in 
saline treated rats (Figure 5). Similarly, pulse pressure was significantly increased 
compared to baseline level at all three doses and only increased significantly higher than 
respective values in saline treated group at the lowest and middle doses (Figure 6). 
Infusion of noradrenaline at the highest dose also increased venous pressure significantly 
when compared to both baseline level and the respective value in saline treated group 
(Figure 7). Administration of noradrenaline also significantly increased P mer compared 
to baseline level at all three doses (Figure 8). Moreover, administration of 
noradrenaline at the last two doses significantly increased P mer when compared to 
respective values in saline treated group (Figure 8). Administration of noradrenaline at 
the lowest and highest doses resulted in significantly increase in dP/dt compared to both 
baseline level and respective values in saline treated group (Figure 9). In contrast, dP/dt 
remained at the baseline level at the middle dose and was not significantly different from 
the respective value in saline treated rats (Figure 9). The middle and highest dose of 
noradrenaline significantly increased heart rate compared to both baseline level and 
50 
4QL---------~---------L--------~--------~----------
c 01 02 03 
Time 
Figure 4 Percent change in fistula flow index during administration of arginine 
vasopressin (AVP; 10, 30, 100 nglkg/min), sodium nitroprusside (SNP; 100, 300, 
1000 ng/kglmin), noradrenaline (NA; 1, 3, 10 p.g/kglmin), and saline (0.002, 0.006, 
0.02 ml/min) in thiobutabarbital anaesthetized rats with chronic arteriovenous 
fistula (5 weeks post shunt) in three increasing doses over the course of time. C, 
control; D1, dose 1; D2, dose 2; D3, dose 3. The duration of each infusion was 
18-20 min. Data represents mean value± SEM. 
aSignificantly different from the baseline level; P < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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Figure 5 Percent change in blood pressure during administration of argmme 
vasopressin (AVP; 10, 30, 100 ng/kg/min), sodium nitroprusside (SNP; 100, 300, 
1000 ng/kg/min), noradrenaline (NA; 1, 3, 10 Jlg/kg/min), and saline (0.002, 0.006, 
0.02 ml/min) in thiobutabarbital anaesthetized rats with chronic arteriovenous 
fistula (5 weeks post shunt) in three increasing doses over the course of time. C, 
control; D1, dose 1; D2, dose 2; D3, dose 3. The duration of each infusion was 
18-20 min. Data represents mean value± SEM. 
8 Significantly different from the baseline level; P < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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Figure 6 Percent change in pulse pressure during administration of arginine 
vasopressin (AVP; 10, 30, 100 ng/kg/min), sodium nitroprusside (SNP; 100, 300, 
1000 ng/kg/min), noradrenaline (NA; 1, 3, 10 f.lg/kg/min), and saline (0.002, 0.006, 
0.02 ml/min) in thiobutabarbital anaesthetized rats with chronic arteriovenous 
fistula (5 weeks post shunt) in three increasing doses over the course of time. C, 
control; D1, dose 1; D2, dose 2; D3, dose 3. The duration of each infusion was 
18-20 min. Data represents mean value± SEM. 
3 Significantly different from the baseline level; P < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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Figure 7 Percent change in venous pressure during administration of arginine 
vasopressin (AVP; 10, 30, 100 ng/kg/min), sodium nitroprusside (SNP; 100, 300, 
1000 ng/kg/min), noradrenaline (NA; 1, 3, 10 J.lg/kg/min), and saline (0.002, 0.006, 
0.02 ml/min) in thiobutabarbital anaesthetized rats with chronic arteriovenous 
fistula (5 weeks post shunt) in three increasing doses over the course of time. C, 
control; D1, dose 1; D2, dose 2; D3, dose 3. The duration of each infusion was 
18-20 min. Data represents mean value± SEM. 
8 Significantly different from the baseline level; P < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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Figure 8 Percent change in Pmcr during administration of arginine vasopressin (AVP; 
10, 30, 100 ng/kg/min), sodium nitroprusside (SNP; 100, 300, 1000 ng/kg/min), 
noradrenaline (NA; 1, 3, 10 J.lg/kg/min), and saline (0.002, 0.006, 0.02 mVmin) in 
thiobutabarbital anaesthetized rats with chronic arteriovenous fistula (5 weeks post 
shunt) in three increasing doses over the course of time. C, control; D1, dose 1; D2, 
dose 2; D3, dose 3. The duration of each infusion was 18-20 min. Data represents 
mean value± SEM. 
8 Significantly different from the baseline level; P < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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Figure 9 Percent change in dP/dt during administration of arginine vasopressin 
(AVP; 10, 30, 100 ng/kg/min), sodium nitroprusside (SNP; 100, 300, 1000 ng/kg/min), 
noradrenaline (NA; 1, 3, 10 Jlg/kg/min), and saline (0.002, 0.006, 0.02 ml/min) in 
thiobutabarbital anaesthetized rats with chronic arteriovenous·fistula (5 weeks post 
shunt) in three increasing doses over the course of time. C, control; D1, dose 1; D2, 
dose 2; D3, dose 3. The duration of each infusion was 18-20 min. Data represents 
mean value ± SEM. 
8 Significantly different from the baseline level; P < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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Figure 10 Percent change in heart rate during administration of argmme 
vasopressin (AVP; 10, 30, 100 nglkg/min), sodium nitroprusside (SNP; 100, 300, 
1000 ng/kg/min), noradrenaline (NA; 1, 3, 10 J.lg/kg/min), and saline (0.002, 0.006, 
0.02 mllmin) in thiobutabarbital anaesthetized rats with chronic arteriovenous 
fistula (5 weeks post shunt) in three increasing doses over the course of time. C, 
control; D1, dose 1; D2, dose 2; D3, dose 3. The duration of each infusion was 
18-20 min. Data represents mean value± SEM. 
3Significantly different from the baseline level; p < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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respectivy values in saline treated group (Figure 10). Noradrenaline infusion 
significantly increased TPR compared to baseline at the lowest and highest doses as well 
as elevated resistance to venous return at all three doses (Figure 11, 12). Moreover, 
infusion of noradrenaline also significantly increased resistance to venous return when 
compared to respective values in saline infused group at all doses (Figure 12). Infusion 
of noradrenaline did not change resistance of fistula when compared to either baseline 
level or respective values in saline treated rats (Figure 13). Systemic resistance was 
significantly higher compared to baseline level at the lowest and highest dose while it 
was only significantly higher than the respective value in saline treated group at the 
highest dose (Figure 14). 
3.3. Haemodynamic effects of arginine vasopressin in rats with chronic AVF 
The baseline values are available from Table 4. Impact of AVP on cardiac output was 
very limited (Figure 2). At the middle and highest doses of AVP infusion, fistula flow 
index increased significantly compared to respective values in saline treated group 
(Figure 4). However, there was not any alteration in systemic flow index compared to 
both baseline level and respective values in saline treated rats (Figure 3). Infusion of 
AVP at the last two doses significantly increased blood pressure when compared to 
respective values in saline treated group (Figure 5). Moreover, AVP infusion at the 
highest dose significantly increased blood pressure when compared to the baseline value 
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Figure 11 Percent change in total peripheral resistance during administration of 
arginine vasopressin (AVP; 10, 30, 100 nglkg/min), sodium nitroprusside (SNP; 100, 
300, 1000 nglkglmin), noradrenaline (NA; 1, 3, 10 Jlglkglmin), and saline (0.002, 
0.006, 0.02 ml/min) in thiobutabarbital anaesthetized rats with chronic 
arteriovenous fistula (5 weeks post shunt) in three increasing doses over the course 
of time. C, control; D1, dose 1; D2, dose 2; D3, dose 3. The duration of each 
infusion was 18-20 min. Data represents mean value± SEM. 
8Significantly different from the baseline level; p < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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Figure 12 Percent change in resistance to venous return during administration of 
arginine vasopressin (AVP; 10, 30, 100 ng/kg/min), sodium nitroprusside (SNP; 100, 
300, 1000 ng/kg/min), noradrenaline (NA; 1, 3, 10 pg/kg/min), and saline (0.002, 
0.006, 0.02 ml/min) in thiobutabarbital anaesthetized rats with chronic 
arteriovenous fistula (5 weeks post shunt) in three increasing doses over the course 
of time. C, control; D1, dose 1; D2, dose 2; D3, dose 3. The duration of each 
infusion was 18-20 min. Data represents mean value± SEM. 
8 Significantly different from the baseline level; P < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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Figure 13 Percent change in resistance of fistula during administration of arginine 
vasopressin (AVP; 10, 30, 100 ng/kg/min), sodium nitroprusside (SNP; 100, 300, 
1000 ng/kg/min), noradrenaline (NA; 1, 3, 10 J.lg/kg/min), and saline (0.002, 0.006, 
0.02 ml/min) in thiobutabarbital anaesthetized rats with chronic arteriovenous 
fistula (5 weeks post shunt) in three increasing doses over the course of time. C, 
control; Dl, dose 1; D2, dose 2; D3, dose 3. The duration of each infusion was 
18-20 min. Data represents mean value± SEM. 
3Significantly different from the baseline level; P < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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Figure 14 Percent change in systemic resistance during administration of arginine 
vasopressin (AVP; 10, 30, 100 nglkg/min), sodium nitroprusside (SNP; 100, 300, 
1000 nglkglmin), noradrenaline (NA; 1, 3, 10 Jlg/kglmin), and saline (0.002, 0.006, 
0.02 ml/min) in thiobutabarbital anaesthetized rats with chronic arteriovenous 
fistula (5 weeks post shunt) in three increasing doses over the course of time. C, 
control; D1, dose 1; D2, dose 2; D3, dose 3. The duration of each infusion was 
18-20 min. Data represents mean value± SEM. 
3Significantly different from the baseline level; P < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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(Figure 5). In contrast, administration of AVP did not significantly alter pulse pressure 
and venous pressure compared to both baseline level and respective values in saline 
treated rats (Figure 6, 7). The highest dose of AVP significantly increased Pmcf 
compared to both baseline value and the respective value in saline treated group (Figure 
8). Infusion of AVP at the highest dose also. significantly increased dP/dt when 
compared to the respective value in saline treated group (Figure 9). However, there was 
no alteration in heart rate during the infusion of AVP (Figure I 0). At the highest 
administrated dose of AVP, resistance to venous . return increased significantly when 
compared to the baseline level (Figure 12). Administration of AVP at the highest dose 
did not significantly change TPR and systemic resistance compared to both baseline 
levels and respective values in saline treated rats (Figure 11, 14). As well, resistance of 
fistula did not alter significantly compared to both baseline levels and respective values 
in saline treated rats (Figure 13 ). 
3. 4. Haemodynamic effects of sodium nitroprusside in rats with chronic AVF 
The baseline values are available from Table 4. Administration of SNP did not change 
cardiac output significantly (Figure 2). While there was no change in systemic flow 
index, the highest dose of SNP administration significantly decreased fistula flow index 
when compared to the baseline level (Figure 3, 4). The highest dose of SNP 
significantly decreased blood pressure compared to the baseline level (Figure 5). In 
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contrast,, administration of SNP did not alter pulse pressure (Figure 6). As well, 
infusion of SNP at the highest dose did not significantly change the venous pressure 
when compared to the respective value in the saline treated group (Figure 7). Similarly, 
SNP infusion had very limited effect on P mer (Figure 8). The highest administrated dose 
of SNP significantly decreased dP/dt when compared to the baseline level (Figure 9). In 
contrast, infusion of SNP did not alter heart rate (Figure 1 0). Similarly, infusion of SNP 
did not change TPR, resistance to venous return, systemic resistance and resistance of 
fistula when compared either to baseline level or respective values in saline treated group 
(Figure 11, 12, 13, and 14). 
3. 5. Haematocrit, plasma volume and total blood volume 
In both fistula and sham-operated group, haematocrit decreased significantly compared 
to baseline level at the highest dose of saline infusion (Table 5). However, there is no 
significant difference between the two groups. Plasma volume and total blood volume 
were significantly lower in sham-operated group compared to respective values in 
fistula-saline treated group. AVP dose dependently decreased haematocrit compared to 
baseline level and respective values in saline treated group. Similarly, administration of 
AVP increased plasma volume significantly compared to baseline level. Moreover, the 
middle dose of AVP infusion increased total blood volume significantly when compared 
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Table 5 Haematocrit (Hct), plasma volume and total blood volume values during 
administr~tion of noradrenaline (NA; n = 7; 1, 3, 10 Jlg/kg/min), arginine 
vasopressin (AVP; n = 5; 10, 30, 100 n4g/kglmin), sodium nitroprusside (SNP; n = 6; 
100, 300, 1000 nglkg/min), and saline (n = 6; 0.002, 0.006, 0.02 ml/min) in 
thiobutabarbital anaesthetized rats with chronic arteriovenous fistula (5 weeks post 
shunt) and sham-operated rats infused with saline (n = 8; 0.002, 0.006, 0.02 ml/min) 
(C, control measurement; M1, measurement 1; M2, measurement 2; M3, 
measurement 3) (n =8; 0.002, 0.006, 0.02 ml/min). The duration of each infusion 
was 18-20 min. Each value represents mean ± SEM. 
Hct Plasma volume Total blood volume 
NA 
c 0.53 ± 0.007 23.2 ± 0.99 37.1 ± 1.54 
M1 0.53 ± 0.005 24.0 ± 1.59 38.6 ± 2.43 
M2 0.54 ± 0.008 23.5 ± 1.63 37.9 ± 2.52 
M3 0.54 ±0.009 23.2 ± 1.78 37.8 ± 2.79 
AVP 
c 0.53 ± 0.012 20.6 ± 1.21 32.9 ± 2.00 
MI 0.48 ± 0.009" 24.3 ± 1.48" 37.0 ± 2.17 
M2 0.47 ± 0.007"b 24.8 ± 1.773 37.3 ± 2.633 
M3 0.46 ± 0.007"b 24.8± 1.71 3 36.8 ± 2.68 
SNP 
c 0.54 ± 0.011 23.2 ± 1.22 37.7 ± 1.63 
M1 0.52 ± 0.014 23.8 ± 1.46 37.8 ± 1.95 
M2 0.52 ± 0.013" 25.5 ± 1.25" 40.4 ± 1.55 
M3 0.51 ± 0.012" 26.5 ± 2.37" 41.5 ± 3.23 
Saline 
c 0.53 ±0.011 22.2 ± 1.54 35.7 ± 2.25 
M1 0.53 ± 0.011 20.8 ± 1.00 33.1 ± 1.46 
M2 0.51 ± 0.008 21.5 ± 0.90 33.6 ± 1.33 
M3 0.51 ± 0.007" 22.0 ± 1.12 34.3 ± 1.53 
Sham 
c 0.54 ± 0.012 19.5 ± l.OOb 31.6 ± 1.87b 
Ml 0.51± 0.009 20.0 ± 1.26b 31.6 ± 1.88b 
M2 0.51± 0.006 19.7 ± 1.25b 30.8 ± 1.92b 
M3 0.50 ± 0.007" 19.2 ± 1.16b 29.8 ± 1.81b 
•significantly different from the baseline level; P < 0.05 
bSignificantly different from the respective value in saline treated group; P < 0.05 
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to the b~seline level. As well, infusion of SNP decreased haematocrit and therefore 
increased plasma volume significantly compared to baseline level. In contrast, SNP 
infusion at all three dose levels did not significantly change total blood volume. 
Administration of noradrenaline had very limited effects on haematocrit, plasma volume, 
and total blood volume (Table 5). 
3. 6. Organ weight and body weight 
The weight of the right ventricle in rats with chronic AVF (n =6) was 48.5% higher than 
the respective value in sham-operated group (n = 8). As well, left ventricle plus septum 
in rats with chronic AVF was 21.2% higher than respective value in sham-operated group 
(Table 6). Not surprisingly, the weight ratio of right ventricle to left ventricle plus 
septum increased significantly in rats with chronic AVF infused with saline when 
compared to the respective value in sham-operated group. In the group administrated 
with noradrenaline, the weights of left and right kidneys were heavier than respective 
values in saline treated group by 14.2% and 14.9% respectively (Table 6). 
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Table 6. Weights of wet lung (WL; g), dry lung (DL; g), weight ratio of dry lung to 
wet lung .(DL/WL), weights of right kidney (RK; g), left kidney (LK; g), right 
ventricle (RV; g), left ventricle plus septum (LVS; g), and weight ratio of right 
ventricle to left ventricle plus septum (RV ILVS) after administration of 
noradranline (NA; n = 7), arginine vasopressin (AVP; n = 5), sodium nitroprusside 
(SNP; n = 6), and saline (n = 6) in thiobutabarbital anaesthetized rats with chronic 
arteriovenous fistula (5 weeks post shunt) and sham-operated rats infused with 
saline (n = 8; 0.002, 0.006, 0.02 mllmin) and mean body weight in each group (BW; 
g). Each value represents mean ± SEM. 
AVP SNP NA Saline Sham 
WL 4.62 ± 0.44 3.54 ± 0.12 3.94 ± 0.44 3.50 ± 0. 30 3.07 ± 0.31 
DL 1.02 ± 0.20 0.84 ± 0.05 1.20 ± 0.32 1.06 ± 0.22 0.82 ± 0.04 
DLIWL 0.26 ± 0.04 0.23 ± 0.03 0.24 ± 0.01 0.28 ± 0.07 0.28 ± 0.03 
RK 3.61 ± 0.19 3.35 ± 0.12 4.16 ± 0.09* 3.62 ± 0.19 3.48±0.45 
LK 3.72 ± 0.26 3.41±0.12 4.03 ± 0.07* 3.53 ± 0.24 3.81±0.13 
RV 1.05 ± 0.06 1.05 ± 0.06 0.87 ± 0.11 0.98 ± 0.06 0.66 ± 0.04* 
LVS 2.82 ± 0.09 2.59 ± 0.13 2.88 ± 0.07 2.63 ± 0.14 2.17 ± 0.06* 
RV/LVS 0.37 ± 0.03 0.33 ± 0.02 0.32 ± 0.02 0.37 ± 0.02 0.30 ± 0.01* 
BW 457 ± 18 480± 8 481 ± 14 480 ± 21 457 ± 16 
*significantly different from respective values in saline treated group; P < 0.05 
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4. Discussion 
In the present study, the haemodynamic changes in rats with chronic AVF were 
investigated. Specifically, the effect of vasoactive agents, NA, AVP, and SNP were 
studied. The most striking observation was the lack of significant change in cardiac 
output following treatment with vasoactive agents despite significant changes in preload 
and afterload in the presence of chronic AVF. 
In accordance with Huang et al., (1992) the daily increase in body weight of rats with 
chronic AVF was similar with the increment in body weight in sham-operated rats 
(Huang et a/., 1992). Perhaps, the two most reasonable explanations for such an 
observation are: 1) the rats with chronic AVF did not develop heart failure, therefore no 
fluid retention occurred; and 2) the rats with chronic AVF gained weight by fluid 
retention due to high output heart failure but tend to lose adipose tissue due to the stress 
of having a fistula. However, it is unlikely that the existence of heart failure was 
responsible for an edematous state since there was no change in the weight ratio of dry 
lung to wet lung between rats with chronic fistula compared to sham-operated rats. 
The CI of rats with chronic AVF in the present study was 36.65 ml/min per 100 g which 
translated into an 82.9 % increase compared to the respective value in sham-operated 
group at baseline. The level of CI was higher than reported by Flaim et al. ( 1979) but 
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lower than that reported by Huang et al. (1992) and Liu et al. (1991). Similar to 
previous reports, blood pressure, pulse pressure and venous pressure were not 
significantly changed in rats with chronic AVF when compared to sham-operated rats 
(Guyton & Sagawa, 1961; Flaim et al., 1979; Huang et al., 1992). As expected, TPR 
decreased significantly in rats with chronic fistula. As well, resistance to venous return 
also decreased significantly in rats with chronic fistula compared to the respective value 
in sham-operated rats, while there is no report of this parameter being measured in rats 
with chronic AVF in the current literature. Elevation of PGVR and expansion of blood 
volume may be the contributory factors for the reduction in resistance to venous return. 
Also, chronic AVF had limited impact on the heart rate (Nickerson et al., 1951 a; Huang 
et al., 1992; Wang et al., 2003) and observations in the present study support the view. 
Although there is no apparent change in dP/dt in rats with chronic AVF compared to 
sham-operated rats, the alteration of cardiac contractility in rats with chronic AVF may 
have been masked by the simultaneous increase in preload and decrease in afterload. 
An increase in contractility could likely be the result of cardiac hypertrophy in rats with 
chronic AVF. This view is supported by the fact that the ratio of right ventricle weight 
to left ventricle plus septum weight increased in rats with chronic AVF (0.37 ± 0.03; 
mean± SEM, n = 6) compared to the respective value in sham-operated rats (0.30 ± 0.01; 
mean ± SEM, n = 8). As reported previously, total blood volume and plasma volume 
increased significantly in rats with chronic fistula when compared to respective values in 
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sham-op~rated rats (Epstein & Ferguson, 1955; Gratama et al., 1992). However, 
haematocrit in the present study did not change significantly which indicated a 
simultaneous elevation of blood cell volume. In contrast, Epstein & Ferguson (1955) 
reported a significant decrease in arterial haematocrit after creation of fistula in 
experimental dogs compared with haematocrit prior to fistula. Similarly, Gratama et al. 
(1992) recorded lower haematocrit in lambs with aorto-pulmonary left-to-right shunt than 
control. A reasonable explanation tor the discrepancy could be due to difference in 
species, size and duration of the AVF. In accordance with the previous study done by 
Guyton & Sagawa (1961), we found an increase in Pmcf by 38.2% in rats with chronic 
AVF compared to P mcf in sham-operated rats. The increase in P mer is most likely due to 
the increase in blood volume. 
In the present investigation, the existence of chronic fistula increased cardiac output. 
The following haemodynamic factors changed compared to respective values in 
sham-operated rats: 1) TPR and resistance to venous return decreased; 2) heart rate did 
not change and there was no apparent change in cardiac contractility based on dP/dt 
values recorded; and 3) blood volume and Pmcf increased. The augmentation of blood 
volume, Pmcf and reduction in vascular resistance together contributed to the increase in 
cardiac output. 
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Here~ administration of noradrenaline did not significantly increase CI, moreover, 
noradrenaline infusion also did not change systemic flow index while increasing fistula 
flow index. The latter observation contrast those reported by Nakano (1968) in which 
administration of noradrenaline increased cardiac output, shunt flow and systemic flow in 
dogs. This difference could be due to different species and experimental design. It is 
evident that Nakano (1968) quickly administrated noradrenaline (1 J..lglkg) as a single 
bolus injection. In contrast, in the present study, noradrenaline was infused 
continuously for 18-20 min to reach a steady state.· Similar to his study, blood pressure 
was significantly increased by all the three doses (Nakano, 1968). Contrary to our study, 
heart rate was decreased in Nakano's study. Since noradrenaline was administrated in a 
single dose injection, the positive chronotropic action of the drug might·be masked by 
acute compensatory vagal reflex activity (Young et al., 1992; Westfall & Westfall, 2006). 
The positive inotropic effect of noradrenaline is mediated by activation of 
B-adrenoceptors in the human ventricular myocardium (Bristow et a/., 1990). However, 
in some cardiovascular diseases such as myocardial infarction, cardiomyopathy, the 
B-adrenoceptors are altered in a manner that the degree of cardiac contraction upon 
B-adrenergic activation is reduced (Bristow et al., 1990). The chronic exposure to 
increased amounts of neurotransmitter released upon myocardial sympathetic activation 
may be responsible for the insensitivity of B-adrenoceptors (Bristow et a!., 1990). In 
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contrast, .Wang et al. (2003) reported a hypersensitivity to ~-adrenoceptor stimulation in 
rats with chronic AVF. Similarly, in the present study we find that dP/dt is increased in 
rats with chronic AVF during noradrenaline infusion. The increase in the degree of 
cardiac contraction is suggested to be caused by the up-regulation of ~~-adrenoceptor 
density in the heart (Wang et al., 2005). Such unique change in ~ 1 -adrenoceptor density 
in the rat with chronic AVF compared to other cardiovascular stresses may be related to 
the lack of direct injury to the heart or associated with decreased catecholamine level 
(Wang et al., 2005). 
Administration of noradrenaline in rats with chronic AVF also elicits different 
haemodynamic effects when compared with normal rats. In rats with chronic AVF, TPR 
and systemic resistance were significantly elevated at the lowest and highest dose while 
these were maintained at the control level at the middle dose. The slightly increase in 
cardiac output at the middle dose of noradrenaline infusion may lower the vascular 
resistance. During noradrenaline administration, resistance of fistula did not change 
due to the simultaneous increase in fistula flow index and blood pressure difference 
between vein and artery. The latter phenomenon indicates the absence of 
a-adrenoceptor in big vessels or the non-distensible property of the fistula. 
Administration of noradrenaline significantly increased venous pressure in rats with 
chronic AVF. The reason for the latter might be that the high arterial pressure was 
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transmitted into the venous system directly through the AVF. 
Infusion of noradrenaline increased blood pressure, pulse pressure (Takacs, 1965; Bower 
& Law, 1993), Pmcr, resistance to venous return which is similar to its action in normal 
rats (Imms et al., 1974; Pang & Tabrizchi~ 1986; Bower & Law, 1993; Tabrizchi, 2001). 
Haematocrit did not change during noradrenaline administration (Floyer & Morris, 1976; 
Aziz & Sommer, 1982). Since there is a fall in haematocrit value in saline treated 
sham-operated rats and rats with chronic AVF in the present study, administration of 
noradrenaline should have a hemo-concentrating effect. 
In the present investigation, the weight of right and left kidneys were significantly 
increased in animals that received noradrenaline compared to respective values in saline 
treated group. As early as 1922, there was description of swelling of kidney during 
catecholamine infusion (Richards & Plant, 1922). The possible explanation could be 
that administration of noradrenaline: 1) increased capillary pressure filtration fraction by 
constricting efferent glomerular arterioles which resulted in fluid retention in kidneys; 2) 
activated the renin-angiotensin-aldosterone system through ~-adrenoceptor stimulation; 
or 3) directly elicited tubular electrolyte and water reabsorption (Osswald & Greven, 
1981 ). Moreover, it has long been recognized that reduction of blood flow to the kidney 
may lead to ischemia injury (Bellomo & Giantomasso, 2001; Westfall & Westfall, 2006). 
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Also, nm:adrenaline has been used to establish a reversible model of acute renal failure 
(Cronin et al., 1978). In the latter study, acute renal failure was induced by the infusion 
of noradrenaline (0.75 jlg/kg/min) directly into renal artery for 40 minutes. Although 
different from the present experimental design, in which noradrenaline was administrated 
at higher doses (1, 3, 10 jlg/kg/min) and for a longer period (60 minutes for three doses), 
suspicion of renal ischemia could be raised. The ischemia injury led to a decrease in 
endothelial cell motility and surface area (Kaufman et al., 1987). The damage of 
endothelium resulted in an increase in vascular permeability and leak of fluid into the 
interstitial tissue which is indicated by renal weight gain (Kaufman et a!., 1987). 
In summary, administration of noradrenaline did not change CI in rats with chronic AVF. 
The positive effects of noradrenaline on heart rate, cardiac contractility, and total body 
venous tone tended to increase CI. However, the increase of CI at the highest dose may 
have been prevented due to the increase in TPR and resistance to venous return. 
Unlike its actions in animals without chronic AVF, administration of AVP did not change 
CI in rats with chronic AVF (Share, 1988). As previously reported, blood pressure 
increased during administration of AVP (Tabrizchi & Ford, 2004). In the present animal 
model, blood pressure increased while pulse pressure, venous pressure, and heart rate 
were unaffected during AVP infusion. 
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Consistent with a previous report, infusion of AVP increased dP/dt (Tabrizchi & Ford, 
2004). It has been demonstrated that AVP, via V1-receptor activation, evokes 
concentration-dependent increases in [Ca2li in cultured neonatal rat myocardiocytes (Xu 
& Gopalakrishnan, 1991; Liu et a!., 1999). Therefore, administration of AVP is able to 
increase cardiac contractility by stimulating V 1-receptor. In contrast, left ventricular 
dP/dtmax dose dependently decreased during administration of AVP (0.12-4 mU/kg/min) 
in pentobarbitone-anaesthetised dogs (Yatsu et at., 2002). Myocardial ischemia and 
cardiosuppression seco~dary to the parasympathetic stimulation may contribute to the 
reduction in dP/dt (Yatsu eta/., 2002). When coronary perfusion is kept constant (15 
ml/min), the contractility of isolated rat heart displays biphasic effect upon AVP infusion, 
while dP/dtmax increased at the lower concentrations (50 and 100 pg/ml) it decreased at 
higher concentrations of 400 and 500 pg/ml infusion (Walker et a/., 1988). In the 
present study, the increment in P mcf and total blood volume increase the fullness of the 
circulation. This in turn would elevate the coronary filling pressure. As a 
consequence, coronary vasoconstriction and myocardial ischemia will be reduced. 
Cardiac contractility increased due to direct cardiac stimulating action of AVP via V 1 
receptor. 
In accordance with Floyer and Morris (1976), we reported a decrease in haemactocrit 
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together ,with an increase in plasma volume and total blood volume. According to 
Tabrizchi & Ford (2004), there is no change in haematocrit, plasma volume, and total 
blood volume. The existence of chronic AVF and higher de>se of AVP administration 
may be the reason for the difference from the previous work in our lab (1, 3, 10 
ng/kg/min vs. 10, 30, 100 ng/kg/min) (Tabrizchi & Ford, 2004). The increase in total 
blood volume was supposed to be mediated via V2 receptor (Jackson, 2006). Exposure 
to AVP for a period of 40 min leads to translocation of water channel-containing vesicles 
to plasma membrane (Nielsen et a/., 1995; Jackson, 2006). Because water 
channel-containing vesicles contain functional water channels (aquaporin 2), the water 
permeability of renal collecting duct cells increases greatly (Jackson, 2006). Moreover, 
Vrreceptor activation also increases Na+ transport in the thick ascending limb and 
collecting duct which also helps to increase water reabsorption (Jackson, 2006). As 
well, we recorded a significant increase in P mcf at the highest dose of AVP infusion in rats 
with chronic AVF. There might be two explanations: 1) the highest dose of AVP 
administration contracted veins directly; and 2) an increase in total blood volume 
elevated the fullness of the vasculature. 
In contrast to noradrenaline administration, the weights of kidneys did not mcrease 
significantly after AVP treatment when compared to saline treated group. This is 
because AVP increase vascular resistance most prominently in stomach, small and large 
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intestines, muscles, and skin vascular beds (Charocopos et al., 1982). Therefore, no 
change in the wet weights of kidneys was observed inAVP administrated rats. 
In summary, in rats with <O:hronic AVF, administration of AVP did not change the Cl. 
Unlike its actions in normal rats, administration of AVP in rats with chronic AVF reverse 
the preload-afterload mismatch by increasing P mer and total blood volume with little 
effect on resistance to venous return. Therefore, CI did not fall despite elevation of the 
afterload. 
Administration of SNP had limited effects on CI in our present study. As reported by 
O'Rourke et a/. (1982), infusion of SNP did not change blood pressure at 1.2 J.tg/kg/min 
but decreased blood pressure at the dose of 1.8 J.tg/kg/min in conscious dogs with chronic 
AVF. In present study, blood pressure also decreased at the highest dose while no 
alterations in pulse pressure, venous pressure, and P mer were observed. The lack of 
decrease in P mcf may be caused by an increase in plasma volume. Since SNP has a 
vasodilator effect, it might reduce the capillary pressure and remove the fluid from 
interstitial to the intravascular space according to Starling equation (Gabel & Drake, 
1979). The latter process may be mediated by the kidney because no change in 
haematocrit and plasma volume was observed in nephrectomized rats (Almeida et al., 
1986). Fistula flow index decreased significantly at the highest dose due to the 
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reduction. in the pressure difference between the artery and vein. As well, similar to its 
actions in pentobarbital anaesthetized dogs without AVF, SNP administration did not alter 
TPR and resistance venous return due to baroreflex activation (Ogilvie & 
Zborowska-Sluis, 1991 ). Contrary to the study of O'Rourke et al. (1982) in which left 
ventricle dP/dtmax was increased, we found no change in dP/dt at the lowest and middle 
dose of SNP administration but a significant decrease in dP/dt at the highest dose. It has 
been demonstrated that there are no direct inotropic and chronotropic actions of SNP on 
isolated heart. Also, in the present study there is limited change in preload and 
afterload during the administration of SNP. Therefore, the fall in dP/dt may due to the 
increase of compliance in the wall of heart caused by nitric oxide pathway. 
In summary, administration of SNP has limited effects on CI in rats with chronic AVF. 
In rats with chronic AVF, the transmission of arterial pressure to distensible large veins 
increased venous capacitance (Epstein & Ferguson, 1955). As well, TPR is set at very 
low level due to the existence of AVF, further infusion of SNP had little impact on TPR 
based on Ohm's law. Since SNP reduces venous return by increasing venous 
capacitance and reduce TPR, the effects of the drug were nullified in our working animal 
model. As well, it has been demonstrated that many blood vessels dilate in response to 
an increase in blood flow (Corretti et al., 2002). A principal mediator of flow mediated 
vasodilation is supposed to be endothelium-derived nitric oxide (Corretti et al., 2002). 
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Moreover, endothelial nitric oxide synthase gene transcription is activated when exposed 
to high flow for a longer period of time (hours) and this can result in continued increase 
in nitric oxide generation (Corretti et al., 2002). The up-regulation of nitric oxide 
s:y~thesis might be another reason for the lack of response to SNP administration in rats 
with chronic AVF. In conclusion, due to the special condition in our experimental 
model, administration of SNP had limited haemodynamic effects on rats with chronic 
AVF. 
In the present study we managed to increase the vascular resistance by administration of 
noradrenaline or AVP, elevate heart pumping capacity and total body venous tone by 
infusion of noradrenaline. Nevertheless, despite these circulatory alterations, CI did not 
change. One explanation could be that heart was pumping at the maximal level due to 
the large increase in venous return in rats with chronic AVF according to Frank-Starling 
mechanism. In another words, the heart working reserve was used up to compensate the 
AVF. Higher cardiac performance was not achievable. In the latter condition, further 
increase in cardiac output was prevented by the limited heart pumping capacity. 
Therefore, further increment in heart rate, cardiac contractility, and total body venous 
tone were incapable of elevating Cl. Since there was an increase in resistance to venous 
return during the infusion of noradrenaline, CI did not fall. This may be the result of 
simultaneous augmentation of venous return caused by PGVR. Moreover, elevation of 
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systemic ,resistance (resistance of the circulation except the fistula) by 79% and 69% only 
increased TPR by 24% and 2&%, respectively, during infusion of noradrenaline at the 
lowest and highest doses. Therefore, although strong vasoconstrictors such as 
noradrenaline and AVP increased systemic resistance greatly, the increment in resistive 
load against the pumping heart was relatively minor. As a consequence, the CI was not 
changed by noradrenaline or AVP infusion. Unfortunately, we failed to decrease the 
TPR and/or total body venous tone during administration of SNP. This is possibly 
caused by an activation of sympathetic tone (Flaim, 1982). We would be very 
interested to see whether the CI will increase by further decreasing TPR or decrease upon 
the reduction in total body venous tone. We postulate that at a lower dose of vasodilator 
such as SNP or nitroglycerin, cardiac output will decrease due to the decrease in 
ventricular filling. However, when the drug concentration reaches a level high enough 
to reduce blood pressure, systemic vasoconstriction occurs due to sympathetic activation 
to maintain the blood pressure in baroreceptor level and counteracts the cardiac output 
lowering effect of the vasodilators. The latter postulation was supported by the work of 
Flaim ( 1982), in which administration of nitroglycerin at 2, 8 J..lg/kg/min reduced cardiac 
output without affecting mean arterial pressure while failing to reduce the cardiac output 
and mean arterial pressure at 32 J..lglkg/min infusion. Furthermore, we predict that if we 
increase the dose of vasodilator to the level to reduce blood pressure, sympathetic 
activation will not keep the blood pressure at the baroreceptor level and cardiac output 
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will fall. 
In conclusion, in rats with well compensated chronic AVF, vasoactive agents have little 
effects on cardiac output. Therefore, in diseases resembling the pathophysiology of 
chronic AVF such as septic shock, administration of these drugs has little benefit. The 
present work not only sheds light on the future medical intervention in clinical conditions 
resembling the hyper-haemodynamics of chronic AVF but also expands our knowledge 
on the cardiovascular system. 
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